

## **CURRICULUM VITAE**

### ***Shahab Uddin Khan, Ph.D.***

#### **WORK ADDRESS**

Hamad Medical Corporation  
Academic Health System PO. Box 3050  
Doha, Qatar  
Mobile (974)-6679-0586  
Phone (974)-40253220

#### **PERMANENT ADDRESS**

1S279 Michigan Ave, Villa Park, IL 60181, USA  
Phone: 630-447-0558

#### **EMAIL ADDRESS**

[Skhan34@hamad.qa](mailto:Skhan34@hamad.qa) ; [suddinkhan@gmail.com](mailto:suddinkhan@gmail.com)

#### **PERSONAL DATA**

Nationality American  
Marital Status Married

#### **Education**

1982-BS(Hons.)Chemistry, Aligarh Muslim University, India  
1984-MS. Biochemistry, Aligarh Muslim University, India  
1986-MPhil. Biochemistry, Aligarh Muslim University, India  
1988-Ph.D. Biochemistry, Aligarh Muslim University, India

#### **POSTDOCTORAL TRAINING**

1989-199 Postdoctoral Researcher, Department of Radiology, Ohio State University, Columbus, Ohio, USA.  
1991-1996 Postdoctoral Research Associate, Department of Biochemistry & Medicine, Loyola University of Chicago, Maywood, Illinois, USA

#### **ACADEMIC APPOINTMENT**

2015-Present Principal Research Scientist and Head of Molecular Pathophysiology Core, HMC Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar  
2021-Present Adjunct Professor, Cancer Biology, Laboratory of Animal Research Center, Qatar University, Doha, Qatar  
2022-Present Professor, Biosciences, Integral University, Lucknow, India  
2006 -2015 Senior Scientist, Deputy Director, Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia  
2003-2006 Scientist, Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

- 2001-2003                      Research Associate Professor, Department of Medicine, University of Chicago, Illinois, USA
- 1996-2001                      Research Assistant Professor, Department of Medicine, University of Illinois, Chicago, Illinois, USA

**Awards & Honors:**

- 2020-2024                      Listed in 2% top scientist globally by Sandford University/Elsevier/Scopus.
- 2018                              Distinguished individual Award, Medical Research, Hamad Medical Center, Doha, Qatar (Competitively based on annual performance).
- 2017                              Excellence individual Award, Medical Research, Hamad Medical Center, Doha, Qatar (Competitively based on annual performance).
- 2016                              Excellence individual Award, Medical Research, Hamad Medical Center, Doha, Qatar (Competitively based on annual performance).
- 2012                              Best research paper publication award based on impact factor, King Faisal & Specialist Hospital & Research Center, Riyadh, Saudi Arabia (Competitively based on annual performance).
- 2011                              Best research paper publication award based on impact factor, King Faisal & Specialist Hospital & Research Center, Riyadh, Saudi Arabia (Competitively based on annual performance).
- 2010                              Princes Adela Bint Abdullah' Science and Humanitarian award, for Children cancer Research, Riyadh, Saudi Arabia
- 2009                              Best research paper publication award based on impact factor, King Faisal & Specialist Hospital & Research Center, Riyadh, Saudi Arabia (Competitively based on annual performance).
- 2008                              Best research paper publication award based on impact factor, King Faisal & Specialist Hospital & Research Center, Riyadh, Saudi Arabia (Competitively based on annual performance).
- 2006                              Hamdan Rashid Bin Al-Makhtoum award for original research paper, Dubai, UAE
- 2006                              Best research paper publication award based on impact factor, King Faisal & Specialist Hospital & Research Center, Riyadh, Saudi Arabia (Competitively based on annual performance).
- 2005                              Science Achievement Award, King Faisal & Specialist Hospital & Research Center, Riyadh, Saudi Arabia (Competitively based on annual performance).
- 2002                              Young Scientist Award by Asian Indian America, USA
- 1991-1993                      Molecular Biology Program Fellowship, Loyola University, of Chicago, Maywood, Illinois, USA
- 1987-1989                      Senior Research Fellow, Department of Biochemistry, Aligarh Muslim

University, India

- 1985-1986 Junior Research Fellow, Department of Biochemistry, Aligarh Muslim University, India
- 1985-1989 University Grants Commission, India fellowship based on National level exam for granted for five years.
- 1982-1982 MS Merit Scholarship, Department of Biochemistry, Aligarh Muslim University, India

### **MAJOR RESEARCH AREAS**

- (1) Cancer Biology and Translational Research
- (2) Cell biology, biochemistry and molecular biology
- (3) Cytokines and growth factors mediated signaling in human cells.
- (4) Cell cycle and apoptosis

### **Research Statement:**

Aberrant and dysregulated growth and survival signaling pathways are pivotal in the etiology of cancer development. Malignant cells circumvent the normal programmed cell death (apoptosis) through the deregulation of various signaling pathways, enabling their survival and proliferation. Our research aims to identify specific dysregulated molecular targets involved in these processes. Identification of these molecular targets is crucial, as they can serve as prognostic markers for early detection of malignancy. Furthermore, these molecules present attractive opportunities for targeted therapy, enhancing the treatment and management of cancer cells.

### **Teaching Statement :**

My teaching interests align closely with my research pursuits, yet they encompass a broader scope. I have the privilege of teaching, training, and supervising a diverse range of individuals, including scientists, postdoctoral fellows, PhD students, master's students, and undergraduates. In addition to this, I have been actively involved in the education and training of medical fellows, residents, and students for nearly 30 years. I view the role of a teacher as asking to that of a coach for a sports team; each student at various academic levels requires tailored approaches based on their individual knowledge and experience. I find immense joy in teaching and training new students, as it often leads to engaging discussions on broad conceptual topics that are both intellectually stimulating and rewarding.

### **Teaching experiences:** Extensive teaching/Researcher experience

- 1985-1988** Taught cell biology and biochemistry and laboratory methods to BSc. (Honors) and MSc. students at the Department of Biochemistry, Aligarh University, Aligarh, India.
- 1989-1991** Taught and trained laboratory method skills to technician, undergraduate and high school students at the Department of Radiobiology, Ohio State University, Columbus Ohio. Presented research data in scientific meetings and societies.
- 1991-1996** Assisted in graduate teaching program (Molecular biology of Hormone regulation) at Loyola University of Chicago, USA (Molecular biology of Hormone regulation).

- Supervised and trained several graduate, medical residents and fellows to performed research in biomedical research.
- 1996-2001.** Trained and supervised several postdoctoral fellows and undergraduate students at the Department of Medicine, University of Illinois at Chicago, USA
- 2001-2003.** Supervised and trained postdoctoral fellows and lab technicians at Department of Medicine, University Chicago, USA.
- 2003-2015** Taught and supervised Scientists, postdoctoral fellows, undergraduate student High schools' students research methodology, Biology of Cancer, apoptosis. Grant and research paper writing to senior staff member of our team.
- 20015-** Teaching and supervising scientists, Postdoctoral fellows, technicians and Medical students, PhD, Master and undergraduate students at HMC-TRI. Involved in many training programs such as health professional awareness program (HPAP). I am also involved in many committee/supervisory members of master and Ph.D. student's thesis.

**Supervision of students, fellows and scientists:** I have extensive teaching, training and supervising Scientists, Postdoctoral fellows PhD students, Master students and undergraduate (attached table). Few of them have acquired high academic and clinical positions.

### **Master thesis supervisor/co-supervisor/committee member**

#### **Current: Master Student:**

#### **Past Master Student:**

- ❖ **Lubna Zarif**, Master student, College of Arts and Sciences, MS Environmental Science, Qatar University (2020-2021)
- ❖ **Sabah Akhtar**, Master student, College of pharmacy, Qatar University (2019-2020)
- ❖ **Tyabba Akbar Ali**, Master Student, Hamad Bin Khalifa University, Doha Qatar (2019-2020)
- ❖ **Hissa Faleh Al-Thani**. Master Student. College of Biomed, Qatar University (2020-2021). Development and in vivo testing of smart nanoparticles for enhanced anti-cancer activity and reduced cardiotoxicity associated with tyrosine kinase inhibitors.
- ❖ **Elham A. N. Mohamed**, Master Student, College of Biomed, Qatar University (2019-2020). Anti-Cancer Activity of Sanguinarine on Human Papillary thyroid cancer cell line "BC-PAP" by targeting JAK/STAT3 pathway
- ❖ **Salma Younes**, Master Student, College of Biomed, Qatar University (2019-2020). Anticancer Activity of Guggulsterone in Human Leukemic Cells
- ❖ **Zeenath Safira**. Master student, Hamad Bin Khalifa University, Doha Qatar (2018-2019). Long term chemotherapy treatment induces a dual immune resistance in colorectal cancer cells.
- ❖ **Muna Suleiman**, Master student, College of pharmacy, Qatar University, Doha, Qatar (2018-2019). The role of p90 Ribosomal kinase and autophagy in Sunitinib and Ponatinib-induced cardiotoxicity.
- ❖ **Maha AlRomaizan**, Bachelor of Science, Alfaisal University, Riyadh Saudi Arabia (2014). Potent inhibition of mTOR activity using Torin2 inhibits cell viability and induces apoptosis in Epithelial Ovarian Cancer cells
- ❖ **ENSAF M. AL-HUJAILY**, Master student, King Saud University, Riyadh Saudi Arabia (2009) PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells

### **Master thesis examiner**

- ❖ **Layla Ishaq Amiri**. United Arab Emirates University (2016) Effects of Aspirin on Metabolic Alterations in Type 2 Diabetic Rats
- ❖ **Thekra AL-Belooshi**: United Arab Emirates University (2009). Acetaminophen-induced toxicity and mitochondrial dysfunction in murine macrophages in culture

### **PhD. Student supervisor/co-supervisor/committee member**

- ❖ **Zeenat Safira**: Ph.D. student, Hamad Bin Khalifa University, Doha Qatar (2020) . The role of chemotherapy in activating the immunogenic potential of colon adenocarcinoma.
- ❖ **Shilpa Krishnankutty**: Ph.D. student, college Pharmacy, Qatar University, Doha Qatar (2020). Anticancer activity of Neosetophomone-B, an aquatic fungal secondary metabolite, against hematological malignancies.
- ❖ **Lubna Therachiyil**. Ph.D. student, college Pharmacy, Doha, Qatar (2020) Exploring the Role and Involvement of the Ary Hydrocarbon Receptor/cytochrome P450 1A1 Pathway in the Self-Renewal, Proliferation, and Chemoresistance of the Ovarian Cancer Stem Cells.
- ❖ **Sarmadia Ashraf**. Hamad Bin Khalifa University, Doha Qatar (2020) Exosome guided nanoparticles as therapeutic anticancer agents.
- ❖ **Shayista Akbar**. Hamad Bin Khalifa University, Doha Qatar (2020) Exosomes as predictive biomarkers of response to Immunotherapy in Non-small cell lung cancer.
- ❖ **Queenie Fernandes**: Qatar University, College of Medicine (2023) The cooperative role of human Papillomavirus & Epstein-Barr virus on colorectal cancer.
- ❖ **Raheleh Vazehan**: PhD. Hamad Bin Khalifa University, Doha Qatar (2023). Identifying proteins involved in processing DNA double-strand breaks
- ❖

### **Ph.D. thesis examiner**

- ❖ **Nin Sijin Dawn**: PhD candidate: National University of Singapore (2011). Role of Misfolded - Nuclear receptor co-repressor (N-CoR) Induced transcriptional de-regulation In the pathogenesis of acute monocytic leukemia (AML-M5)"
- ❖ **Shoeb Ikhlas**: Ph.D. candidate: Aligarh Muslim University, India (2020). Toxicity assessment of Bisphenol-B, a potential endocrine distributing chemical
- ❖ **Taki Ahmed Khan**: Ph.D. candidate: Aligarh Muslim University, India (2020). Studies on Structural Alteration of Some Monomeric and Multimeric proteins.
- ❖ **Amira Kohl**: PhD. Hamad Bin Khalifa University, Doha Qatar (2024). Deciphering The Functional Biology of E3 Ubiquitin Ligase TRIP12 Using SILAC-Based Quantitative Proteomics Approach
- ❖ **Eman Aldous**: PhD. Hamad Bin Khalifa University, Doha Qatar (2024). Role of Circulating MicroRNAs as Biomarkers for Ischemic Stroke Patients with Type 2 Diabetes-Related Risk Factors

### **Educational Activities**

- October 14, 2005: Enrichment educational program to gifted high school students, King Faisal specialist hospital, Riyadh, Saudi Arabia
- March 11, 2008: Moderator, Basic Science teaching activity to Medical Residents & Fellows

March 22, 2008 Session chair, gene expression profiling, Annual Meeting, Research center, King Faisal Specialist Hospital & Research Center

**Jan 2015-present HMC health professional awareness program (HPAP).**

Volunteer training program for Medical and life sciences students and professional. More than 50 students have been trained in basic and cancer research technologies.

**May 2017-Present: Clinical Fellowship Program:**

This Clinical Fellowship Program focuses on creating awareness for medical fellows regarding the basic and translational cancer research activities that are going at the Translational Cancer Research Facility, iTRI to support the patient care and basic research.

**QU teaching courses:**

**Supervision of students, fellows and scientists:**

I have extensive teaching, training and supervising Scientists, Postdoctoral fellows PhD students, Master students and undergraduate (more than 100). Few of them have acquired high academic and clinical position.

**November 19, 2018: Med1208-elective course assessment:** Evaluated several students for elective training at various Hospital in Qatar.

**PHAR640: Moderated Paper Session Graduate Seminar 1:** Evaluated seminar presentation of master students in College of pharmacy, Qatar University.

**Feb24, 2020: 5-8 PM- Ph.D. students: PHAR720:** Oncology translational research – A hands on approach, Ph.D. students, Qatar University

**March 29, 2020: 3-5 PM-Ph.D. Students:** PHAR720: Ovarian Cancer: an overview; role of stem cells in its pathogenesis, resistance and relapse

April 02, 2020: 3-5PM. MSc Students: PHAR 671: Role of stem cells breast carcinogenesis as well as biomarker and therapeutic target in breast cancers

**Supervision of students, fellows and scientists:** I have extensive teaching, training and supervising Scientists, Postdoctoral fellows PhD students, Master students and undergraduate (attached table). Few of them have acquired high academic and clinical positions.

**MAJOR RESEARCH AREAS**

- (5) Cancer Biology and Translational Research
- (6) Cell biology, biochemistry and molecular biology
- (7) Cytokines and growth factors mediated signaling in human cells.
- (8) Cell cycle and apoptosis

**Currently the main ongoing projects are following**

- ❖ Role of Proteasom /Ubiquitination signaling pathways in carcinogenesis
- ❖ Role FoxM1 in various cancers.
- ❖ PI3-kinase/AKT signaling pathways in promotion of growth/ survival of malignant cells.
- ❖ Fatty Acid Synthase mediated AKT signaling pathway and cancer cell survival.
- ❖ Role of Leptin/Leptin receptor in carcinogenesis of various types of cancers.

- ❖ Curcumin and other natural compounds mediated inhibition of cell proliferation and induction of apoptosis in various cancer cells.

## RESEARCH GRANT/PROPOSAL

### Grant No

### Title/Role

#### As Principal Investigator

- NPRP8-856-2-364.** Microstructure Design of Biocompatible Magnesium Alloys for Biodegradable Medical Implants – In vitro and In vivo Validation. Source: Qatar Foundation:  
**Role: PI.** November 2017-December 2020
- MRC: PR No:16102** Targeting for X- linked Inhibitor of Apoptosis (XIAP) for the treatment of human malignancies. Source: Medical Research Center, Hamad Medical Corporation: **Role: Lead PI:** July 2017- June2021
- MRC: PR No:16354** Targeting deregulated signaling pathways for the treatment of human cancers: Source MRC; Hamad Medical Corporation.  
**Role: Lead PI:** October 2019-Sept 2021
- IRGC-05-SI-18-307** TARGETING OF BREAST CANCER STEM CELLS USING INHIBITORS OF mTOR SURVIVAL PATHWAYS. Source MRC; Hamad Medical Corporation.  
**Role: Lead PI:** July 2020-June 2023.
- MRC-01-20-872** Screening of cytotoxic effects of natural compounds for the treatment of squamous skin cancer. Source MRC; Hamad Medical Corporation.  
**Role: Lead PI:** October 29, 2020-September 2022

#### As Mentor

- IRGC-03-NI-17-070** The effect of migration on the development of Metabolic Syndrome in a group of immigrants to Qatar.  
**Role: Mentor for Kirti Prabhu**
- IRGC-03-NI-17-071** Targeting leukemia stem cell population in acute myeloid leukemia using inhibitors of NF-KB/STAT mediated survival pathways  
**Role: Mentor for KS Siveen**
- IRGC-04-NI-17-155** Targeting S-phase kinase associated protein 2 (SKP2) for colon cancer treatment  
**Role: Mentor for Abdul Q Khan**
- MRC-01-18-186** Role of CDK inhibitor p21 and p27 in human oral squamous cell carcinoma and their potential as therapeutic target  
**Role: Mentor for Abdul Q Khan**

<b>MRC-01-19-047</b>	Anticancer potential of Greensporone A, a fungal secondary metabolite, in leukemic cell lines. <b>Role: Mentor for Kirti Prabhu</b>
<b>MRC-01-19-169</b>	JAK/STAT3 signaling is a viable target for the treatment of papillarythyroid carcinoma <b>Role as Mentor for Abdul Khan:</b> -
<b>MRC-01-20-858</b>	Jak/STAT/HMGB1 signalig axis is a viable strategy to induce apoptotic cell death in multiple myeloma cells. <b>Role: Mentor for Kirti Prabhu</b>
<b><u>As a Co- Investigator:</u></b>	
MRC PR No: 16115  Kiveen	Targeting colorectal cancer stem cells using pristimerin, a naturally occurring triterpenoid. PI:K
MRC PR No: 16114	Screening of mangrove Avicinnia marina- A potential candidate of Qatar for anticancer activity PI:K Prabhu
MRC PR No: 16101	An investigation on the association of high risk human papillomavirus (HPV) types with breast cancer in population of Qatar PI: Dr. K Junejo
MRC PR No: 16119	Evaluation of new therapeutic strategies for human chronic myelogenous leukemia and resulting pulmonary complications PI: Fouad Azizi
MRC PR No16127	Two-dimensional gel electrophoresis coupled to mass spectrometry- based proteomics analysis to identify protein biomarkers in breast and lung cancers LPI: R Krishnankutty
MRC PR No: 16062	Pre-clinical Preclinical Study for Validation of Virus-Specific T Lymphocytes Protocol to Be Applied in Patients Undergoing Hematopoietic Stem Cell Transplantation. PI: Afsheen Raza
MRC PR No:17004	Investigation of Anti-Tumor T-Cells Responses Generated in Vitro against NY-ESO-1 Antigenic Protein versus NY-ESO-1-Protein/ NY-ESO-1 -Antibody Immune Complex. PI: Said Dermime
MRC PR 17118	Screening and Characterization of the Humoral and Cellular Immune Responses against the NY-ESO-1 Cancer Testis Antigen in Cancer Patients PI: Said Dermime
Qatar University.	QU screening platform for medical applications: a catalysis-platform for top science, pharma and clinics PI: Serhiy



Souchelnyskiy ( School of Medicine, Qatar University)

Sidra Medical Center.FoxM1-Claudin1 signaling axis in pathophysiology of inflammatory bowel disease  
PI: Ajaz A. Bhat (Sidra Medical Center)

**Successfully completed Research grants/proposals**

May 2017-Feb 2018	Co-Lead PI. May 2017-Feb 2018The molecular link from type 2 diabetes to breast cancer. NPRP 7 - 363 - 3 – 089
June 2015-July 2016	Lead Principal Investigator: Medical Research Center, Hamad Medical Corporation. Targeting of Fbox protein, Ubiquitin ligase, SKP2 by Bortizomib in Chronic Myelogenous Leukemia cells.
Feb 2014-Jan 2015	Co-Investigator: King Abdul Aziz Science & City. Role of XIAP in Pathogenesis of Saudi Arabian Papillary Thyroid Carcinoma.
Feb 2014-Jan 2015	Co-Investigator: King Abdul Aziz Science & City Prognostic Significance of CARD10 in Saudi Colorectal Cancers.
October 2005-Jan 2015	Principal Investigator: King Faisal Specialist Hospital & Research center. Translational Initiative in lymphoid malignancies.
June 26, 2007-Jan 2015	Principal Investigator: King Faisal Specialist Hospital & Research center. Role of PI3-kinase/AKT pathway in epithelial carcinomas.
October 2006-Jan 2015	Co-Investigator: King Faisal Specialist Hospital & Research center. Molecular Signature of Diffuse Large B- Cell Lymphoma (DLBCL), Lung and ovarian Cancer; A pilot study.
October 2006-Jan 2015	Co-Investigator: King Faisal Specialist Hospital & Research Center. Molecular Signature of Cancer: Clinical Significance in Saudi Arabian and European cancer patients.
June 1, 2012- Jan 2015	Co-Investigator: SANAD: Prevalence of Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome in Saudi Pediatric Acute Lymphoblastic Leukemia.
Oct 05, 2012-Jan 2015	Co-Investigator: King Faisal Specialist Hospital & Research center. Identification of c-Met expression and its association with other survival markers for diagnostic purposes and risk stratification in Saudi Arabian Lung Cancer.
Dec 22, 2012-Jan 2015	Co-Investigator: King Faisal Specialist Hospital & Research center. Identifying Molecular Signature of Thyroid Cancer Using Next Generation Sequencing Technology Based on International Cancer genome Consortium (ICGC) Guidelines.
Jan 2010-Dec 2012	Co-Investigator: King Abdul Aziz Science & City Role of c-Met in

	Saudi Arabian papillary thyroid carcinoma for novel therapy (Direc cost 2 million Saudi Riyals)
Jan 2010-Dec 2012	Co-Investigator: King Abdul Aziz Science & City Cyclooxygenase: Target for epithelial Ovarian Cancer Prevention & treatment. (Direc cost 2 million Saudi Riyals)
Jan 2010-Dec 2012	Co-Investigator: King Abdul Aziz Science & City Prognostic Significance of Genetic alteration in Colorectal in Saudi Cancers. (Direc cost 2 million Saudi Riyals)
October 2003- Sept 2010	Principal Investigator: King Faisal Specialist Hospital & Research Center. Role of JAK/STAT & PI3-kinase/AKT pathway in hematological Malignancies.
Jun 2009- May2010	Co-Investigator: SAND: Real-time PCR Assay of Terminal Deoxynucleotidyl Transferase (TdT) for detection of acute lymphoblastic leukemia in cerebrospinal fluid.
Sep 2001-Jan2003\	Principal Investigator, American Cancer Society, Illinois Role of src kinase in interferon signaling Direct cost: \$75000
Jan2002-Dec2003	Co-Investigator, Myeloma Foundation .Role of GSK3 kinase in myeloma therapy. Direct cost 100,000
Jun 2003-Jul2004	Principal Investigator, Wendy Will Foundation <i>Mechanisms of Interferon Induced Cell growth Inhibition.</i> Direct cost: 26,000 for one year

### **Member of Committee/Advisory boards**

- ❖ **2006-2014: Administrative Responsibility as deputy director of Human Cancer Genomic Research (HGCR):** Involved in all management and Research related activity program. Manage hiring, promotion, the research supplies, making budgets for new instrumentation and other required entities in HGCR.

### **Committee & Advisory panel**

- ❖ **Member of Basic Research Committee :Jan 2005-April 2007:**Member of Basic Research Committee, King Faisal Specialist Hospital & Research center, Riyadh. The main responsibility of members of this committee is to evaluate various proposal and progress report (intramural funding).

- ❖ **Scientific committee member November 7-9 2006:** Scientific committee member of KNCCC International Cancer
- ❖ **Member of Chairman committee 2010-21014:** King Faisal Specialist Hospital & Research center, Riyadh. Making and implication of policies related to basic and clinical researches
- ❖ **Grant & Funding Review board member: 20018-current:** Review and evaluates proposal submitted by clinicians and researchers

#### **MEMBER OF PROFESSIONAL SOCIETIES:**

- ❖ American Society of Clinical Oncologist
- ❖ American Society of Cancer Research
- ❖ American Society of Hematology
- ❖ Endocrine Society
- ❖ International Society of Insulin Growth Factor
- ❖ Free Radical Society, India

#### **INVITED LECTURES/SEMINARS**

1. Department of Radiology, Ohio State University, Columbus. Flavonoids induced DNA damage, May 21, 1990
2. Molecular Biology Program, Loyola University of Chicago: Effect of alcohol and its metabolites on pituitary hormones. April 14, 1992.
3. Monsanto Pharmaceuticals, St. Luis, Missouri. Effect of dietary mutagens on DNA, March 15, 1993.
4. Department of Biochemistry, Kuwait University: Role of insulin receptor substrate family in interferon mediated response. September 14, 1994
5. Department of Radiobiology, Wayne Sate University, Detroit. Interferon mediated signal transduction in hematopoietic cells. February 6, 1995
6. Section of Lymphocyte Biology, National Institute of Health, Bethesda: Role of Map kinases in type I interferon action in hematopoietic cells. April 23, 2001
7. Department of Biological Sciences, King Faisal Specialist Hospital and Research Center: Interferon mediated Signal transduction in hematopoetic cells. July 06, 2002.
8. Department of Surgery, University of Alabama, Birmingham, USA, Role of Mapkinase p38 in Interferon mediated Signal Transduction, April 17, 2003.
9. Invited Speaker, Internation meeting of Free radical in Health and nutrition. Curcumin induced apoptosis in Lymphoma, Banglore, India, Jan 10-13, 2005
10. Invited Speaker, Cancer Research Conference (Middle East and North Africa (MENA) Amman Jordan, September 3-4, 2007.  
Inviated speaker, Multiple Myeloma symposium 2018, Doha, Qatar September 17-18, 2018.

#### **Member of Editorial Board:**

Leukemia and Lymphoma 2009-present  
 Translational medicine communications-2020-Present  
 World Journal of Gastrointestinal Pharmacology & Therapeutics (2010-2013) World

Journal of Clinical oncology  
 PLOSone 2015-present  
 Oncobiology and Targets 2015-present

### **MANUSCRIPT REVIEWER**

International Journal of Cancer, Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Endocrinology , Journal of Immunology Journal of critical care, Journal of Interferon Research, Leukemia and Lymphoma' Saudi Medical Journal, Food & Chemical Toxicology, Hematological, BMC-Genomics, Future Medicine, Chem Biol Interact, Food and Chemical Toxicology, British Journal Hematology, Cell Proliferation, Journal of Cancer Research & Clinical Oncology, BMC-Cancer, Current Vascular Pharmacology, Journal of Clinical Endocrinology & Metabolism, Seminar in Cancer Biology, Journal of inflammation, Turkish J. Hematology, Gynecologic Oncology, Int Food Properties, Mol Cell Biochemistry, Nutrient, Oncobiology & Target, Oncotarget, Translational Oncology, J. Integrative Medicine, APJP, Scientific Report, Frontier of Oncology, Frontiers of Epidemiology, Review in Hematology-Oncology, Biomedine Pharmacotherapy, FRBM, Medical Science Monitor.

### **International Grant Reviewer:**

- ❖ 2006: National Medical Research Council, Singapore
- ❖ 2006: The Medical Council Research, South Africa
- ❖ 2016: Academic Research, Qatar University
- ❖ 2017: Ministry of Higher Education, KINGDOM OF SAUDI ARABIA
- ❖ 2018: Leukemia Lymphoma Research.org.UK
- ❖ 2018: Kuwait Foundation for Advancement of Sciences
- ❖ 2019: Kuwait Foundation for Advancement of Sciences

### **Citation Indices (Google Scholar) as of S e p t e m b e r 1 4 , 2 0 2 4 )**

Citations	18986
h-index	77
i10-index	251

### **PUBLICATIONS: (Peer-reviewed)**

1. Akhtar S, Ahmad F, Alam M, Ansari WA, Uddin S, Steinhoff M, Buddenkotte J, Ahmad A, Datsi A. Interleukin-31: the inflammatory cytokine connecting pruritus and cancer. **Front. Biosci (Landmark Ed) 29, 312, 2024.**
2. Zakaria ZZ, Suleiman M, Benslimane FM, Al-Badr M, Siveem KS, Korashy H, **Uddin S**, Mraiche F, Yalcin H. Imatinib and Ponatinib mediated cardiotoxicity in zebrafish embryos and H9c2 cardiomyoblasts. **Molecular Medicine Reports; 30: 187; 2024.**

3. El-Menyar A, Asim M, Khan N, Rizoli S, Mahmood I, Al-Ani M, Kanbar A, Alaieb A, Hakim S, Younis B, Taha I, Jogol H, Siddiqui T, Hammo TA, Abdurraheim N, Alabdallat M, Bahey AA, Ahmed K, Atique S, Chaudry IH, Prabhu K, **Uddin S**, Al-Thani H. Systemic and Cerebro-Cardiac Biomarkers Following Traumatic Brain Injury: An Interim Analysis of Randomized Controlled Clinical Trial of Early Administration of Beta Blockers. **Scientific Report 14:19574; 2024.**
4. Chauhan R , Malhotra L , Gupta A , Dagar G , Mendiratta M, Masoodi T, Hashem S, Marzooqi SA, Das D, **Uddin S**, Ethayathulla A , Sahoo RK , Macha MA , Shankar A, Akil A , Bhat AA, Singh M. Bergenin inhibits growth of human cervical cancer cells by decreasing Galectin-3 and MMP-9 expression. **Scientific Report 14(1):15287, 2024.**
5. Ahmad N, Moton S, Kuttikrishnan S, Prabhu KS, Masoodi T, Ahmad S, **Uddin S**. Fatty Acid Synthase: A Key Driver of Ovarian Cancer Metastasis and a Promising Therapeutic Target. **Pathology- Research & Practice 260:155465, 2024.**
6. Khan AQ, Agha MV, Ahmad F, Anvar R, Sheikhan KS, Mateo J, Alam M, Buddenkotte J, **Uddin S**, Steinhoff M. LCMS-based metabolomics analyses reveal the crucial role of ERK in regulating metabolic reprogramming in human cutaneous T-cell lymphoma. **Cell Proliferation (PMID: 38946222)2024,**
7. Chmielewski PP, Data K, Strzelec B, Farzaneh M, Anbiyaae A, Zaheer U, **Uddin S**, Sheykhi-Sabzehpoush M, Mozdziak P, Zabel M, Dzięgiel P, Kempisty B. Human aging: From underlying mechanisms to pro-longevity interventions. **Aging and Disease (PMID: 38913049 ) 2024.**
8. Khan AQ, Agha MV, Anvar R, Raza SS, Ahmad A, Allam M, Buddenkotte J, Steinhoff M, **Uddin S**. Targeting of S-phase kinase associated protein 2 stabilized tumor suppressors leading to apoptotic cell death in squamous skin cancer cells. **BBA (PMID: 38866114) 2024.**
9. Prabhu KS Jessy S, Kuttikrishnan S, Mujeeb F, Ahmad N, Habiba U, Mariyam Z , Bhat A, **Uddin S**. Anticancer potential, and molecular targets of pristimerin in human malignancies. **Pharmaceuticals 17: 578. 2024.**
10. Prabhu KS, Ahmad F, Mateo J, Leo R, Kuttikrishnan S, Ali TA. Izadi M, Bhat AA, Buddenkotte J, Daryakenari EP, Steinhoff M, **Uddin S**. Bortezomib Induces Apoptosis in Human Skin Cancer Cells Through the regulation of Skp2/p53 axis. **Cell death & Discovery ; 10:225, 2024.**
11. Prabhu KS, Kuttikrishnan S, Ahmad N, Habiba U, Mariyam Z, Bhat AA, **Uddin S**. H2AX: A Key Player in DNA Damage Response and a Promising Target for Cancer Therapy. **Biomedicine & Pharmacotherapy 175:116663; 2024.**
12. Chakithandy S, Nazzal H, Matoug-Elwerfelli M, Narasimhan S, **Uddin S**, Prabhu KS, Zarif L, Mumtaz N, Sharma A, Al-Khelaifi M. Plasma neurological biomarkers as a measure of neurotoxicity in pediatric dental general anesthesia: a prospective observational feasibility study. **Eur Arch Paediatr Dent 25:267-275; 2024.**

13. Khan AQ, Hasan A, Mir SS, Rashid K, Uddin S, Steinhoff M. Exploiting Transcription Factors to Target EMT and Cancer Stem Cells for Tumor Modulation and Therapy. **Seminar Cancer Biology 100:1-16 2024.**
14. Rayan M, Shawkat TS, Hussein OJ, Therachiyil L, *Maayah ZH, Maccalli C*, **Uddin S**, Prehn JHM, Korashy HM. Unlocking the Secrets: Exploring the Influence of the Aryl Hydrocarbon Receptor and Microbiome on Cancer Development. **Biochem Pharmacol 29:33; 2024.**
15. Khan A, Waheed Y, Kuttikrishnan S, Prabhu KS, El-Elimat T, **Uddin S**, Alali FQ, Agouni A. Network pharmacology, molecular simulation, and binding free energy calculation-based investigation of Neosetophomone B revealed key targets for the treatment of cancer. **Frontiers in Pharmacology: 15:1352907 2024.**
16. Kuttikrishnan S, Prabhu KS, Khan AQ, **Uddin S**. Signaling Networks Guiding Erythropoiesis **Current opinion of Hematology 31:89-95; 2024.**
17. Bhat GR, Sethi I, Sadida H, Rah B, Mir R, Algehainy N, Albalawi IA, Masoodi T, Subbaraj GK, Jamal F, Singh M, Kumar R, Macha MA, **Uddin S**, Haris M, Bhat AA. Cancer Cell Plasticity: From Cellular, molecular, and Genetic Mechanisms to Tumor Heterogeneity and Drug Resistance. **Cancer Metastasis & Review 43:197-228, 2024.**
18. Therachiyil L, Peerapen P, Younis S, Ahmed A, Thongboonkerd V, **Uddin S**, Korashy HM. Proteomic insight towards key modulating proteins regulated by Aryl hydrocarbon receptor involved in carcinogenesis and chemoresistance in ovarian cancer cell lines. **J. Proteomics 295:105108;2024.**
19. Prabhu KS, Sadida HQ, Kuttikrishnan K, Junejo K, Bhat AA. **Uddin S**. Beyond Genetics: Exploring the Role of Epigenetic Alterations in Breast Cancer. **Pathology-Research & Practice 155:174; 254;20024**
20. Patil K, Khan AQ, Ahmad F, Kuttikrishnan S, Anver R Mateo JM, Bhat AA, Buddenkotte J Steinhoff, **Uddin S**. Sanguinarine Triggers Apoptosis in cutaneous Squamous cell Carcinoma cells through ROS-dependent JNK-signaling. **Frontiers landmark 29:40; 2024.**
21. Fernandes Q, Sher G, Prabhu KS, Kuttikrishnan S, Dermime S, Merhi M, Junejo K, Bhat AA, **Uddin S**. Beyond Viral Infections: The Multifaceted Role of Human Papillomavirus and Epstein-Barr Viruses in Shaping the Tumor Microenvironment. **Discovery Medicine 36:1-15; 2024.**
22. Poodineh J, Akhlaghpour A, Ghaedrahmati F, Khojasteh Pour F, Uddin S, Farzaneh M, Azizidoost S., Insights into the Biological Properties of Prostate Cancer Stem Cells: Implications for Cancer Progression and Therapy. **Current Stem Cell Research & Therapy (PMID: 38265390) 2024.**
23. Kuttikrishnan S, Hasan M, Prabhu KS, El-Elimat T, Oberlies NH, Pearce CJ, Alali FQ, Ahmad A, Bhat AA, Yalcin HC, **Uddin S**. Exploring the In Vivo Anti-cancer Potential of Neosetophomone B in Leukemic Cells using a Zebrafish Xenograft Model. **Exp cell research 435:113907; 2024.**
24. Mestiri S, El-Ella DM, Fernandes Q, Bedhiafi T, Almoghrabi S, Akbar S, Inchakalody V, Assami L, Anwar S, **Uddin S**, Zar Gul AR, Al-Muftah M, Merhi M, Raza A, Dermime S. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers. **Biomedicine & Pharmacotherapy 171:116095, 2024.**

25. Ghasemian M, Zehtabi M, Dari MAG, Pour FK, Tabesh GA, Jafari RM, Barati M, **Uddin S**, Farzaneh M. The Emerging Roles of Long Non-Coding RNA (lncRNA) H19 in Gynecologic Cancers. **BMC Cancer 24:4, 2024.**
26. Fernandes Q, Inchakalody VP, Bedhiafi T, Mestiri S, Taib N, Uddin S, Merhi M, Dermime S. Chronic Inflammation and Cancer; The Two Sides of a Coin. **Life Sciences 338:122390; 2024.**
27. Hasan A, Khan NA, **Uddin S**, Khan AQ Steinhoff M. Cancer stem cells, deregulated transcription factors, tumor growth and stemness features: Role of small molecule inhibitors. **Seminar Cancer Biol 98:31-50; 2024**
28. Naeem A, Kumari N, Khan MA, Khan AQ, **Uddin S**, Robertson A, Boltze J, Raza SS. MCC950 reduces autophagy and improves cognitive function by inhibiting NLRP3-dependent neuroinflammation in a rat model of Alzheimer's disease. **Brain Behavior and Immunity 116:70-84; 2024.**
29. Kuttikrishnan S, Ahmad F, Mateo JM, Oberlies NH, Pearce CJ, El-Elimat T, Bhat AA, Feras Alali FQ, **Uddin S**. Neosetophomone B Induces Apoptosis in Multiple Myeloma Cells via targeting of AKT/SKP2 Signaling pathway. **Cell Biology International; 48(2):190-200, 2023.**
30. Kuttikrishnan S, Masoodi T, Sher G, Bhat A, Mateo JM, Ahmad F, Buddenkotte J, Steinhoff M, **Uddin S**. Neosetophomone B-mediated modulation of FOXM1/BUB1B signaling and apoptotic cell death in cutaneous T-cell lymphoma. **J Dermatol Sci . 2023 Oct 6:S0923-1811(23)00224-4.**
31. Idoudi S, Bedhiafi T, Pederson S , Elahtem M, Alremawi I, Akhtar S, Dermime S, Merhi M, **Uddin S**. Role of HMGB1 and its associated signaling pathways in human malignancies. **Cellular Signaling 112:110904; 2023.**
32. Fernandes Q, Khan AQ, Therachiyil L, Bedhiafi T, Korashy HM, Bhat AB, **Uddin S**. Shrinking the Battlefield: The Evolving Role of Nanotherapeutics in Cancer Stem Cell Treatment. **Euor. J. Pharma. Sci; 191:106586; 2023.**
33. Suleiman M, Najjar AA, Zakaria ZZ, Ahmed R, Yalcin H, Korashy H, **Uddin S**, Riaz S, Abdulrahman N, Mraiche F. The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase (TK) Inhibitor Induced Cardiotoxicity. **Journal of Cardiovascular Translational Research 17(2):334-344, 2023.**
34. Abdulrahman N, Leo R, Boumenar H; Ahmad F, Mateo J ; Jochebeth A ; Ansari A, Alam, M, **Uddin S**, Ahmad A, Steinhoff M, Buddenkotte J. Embelin inhibits viability of Cutaneous T Cell Lymphoma Cell Lines HuT78 and H9 by targeting inhibitors of apoptosis. **Leukemia Lymphoma 64:2236-2248; 2023.**
35. Azizidoost S, Nasrolahi A, Sheykhi-Sabzehpoush M, Khoshnam SE, **Uddin S**, Farzaneh M. Signaling Pathways Governing Leukemia Stem Cells Behavior. **Gene & Disease : 11, 830-846, 2023**
36. **Uddin S**, Ahmad A. Proteomic Dissection of Exosome Cargo: Progress and Future Perspectives. **Cancers; 15, 4292, 2023.**

37. Adeeb M, Therachiyil L, Moton S, Buddenkotte J, Alam M, **Uddin S**, Steinhoff M, Ahmad A. Non-coding RNAs in the epigenetic landscape of Cutaneous T-cell lymphoma. **International Review of Cell and Molecular Biology; 380:149-171. 2023.**
38. Abdelaziz N, Therachiyil L, Sadida H, Ali MA, Khan OS, Singh M, Khan AQ, Bhat A, **Uddin S**. Epigenetic inhibitors for cancer treatment. **International Review of Cell and Molecular Biology; 380:211-251, 2023.**
39. Khan NA, Asim M, Biswas KH, Al-Ansari A, Saman H, Sarwar MZ, Osmonoliev K, **Uddin S**. Exosome Nanovesicles as Potential Biomarkers and Immune Checkpoint Signaling Modulators in Lung Cancer Microenvironment: Recent Advances and Emerging Concepts. **J Exp Clin Research 42:221;2023**
40. Waseem A, Khan AQ, Khan MA, Khan R, **Uddin S**, Boltze J, Raza SS. Unveiling the Therapeutic Potential of Non-coding RNAs in Stroke-Induced Tissue Regeneration. **Stem Cells; PMID: 37591309 DOI: 10.1093/stmcls/sxad062 2023.**
41. Chawdhery ZM, Dahri F, **Uddin S**, Junejo J. Pregnancy Associated Acute Pancreatitis: A Practical Approach. Approach. **Surg Med Open Acc J. 5(3). SMOAJ.000612. 2023.**
42. Baloch SS, Khan SR, Tariq M, Wasio A, Ali AA, Shahzadi M, Moosajee M, Anwar S, Raza A, **Uddin S**. Multiple myeloma and its rare paraneoplastic manifestations simmering under the surface. **Pathology-Research & Practice :248:154689, 2023.**
43. Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Marzooqi SA, Chauhan R, Dagar M, Mirza S, Bagga P, Haris M, Reddy R, Akil AA, Macha MA, **Uddin S**, Singh M, Bhat AA. Harnessing the Power of CAR-T Cell Therapy: Progress, Challenges, and Future Directions in Hematological and Solid Tumor Treatments. **J Trans Med 21: 449, 2023.**
44. Farzaneh M, Dari MAG, Anbiyaiee A, Najafi S, Dayer D, Salehi AM, Keivan M, Ghafourian M, **Uddin S**, Azizidoost S. Emerging Roles of Long Non-Coding RNAs NEAT1 in Gynecologic Cancers. **Journal of cell communication and signaling; 17(3):531-547: 2023.**
45. Chandrasekar V, Ansari YM, Singh AV, **Uddin S**, Prabhu KS, Dash S, Al Khodor S, Terranegra A, Avella M, Dakua SP, Investigating the Use of Machine Learning Models to Understand the Drugs Permeability Across Placenta. **IEEE access; 11:52726 2023.**
46. Raza A, Mohsin R, Kanbour A, Gul ARZ, Philip A, Vijayakumar S, Sherif S, Prabhu K, Al-Suwaidi AK, El-Ella DA, Tauro MA, Al-Bozom I, Abualainin WM, Al-Abdulla RAA, Sirriya SA, Hassnad S, **Uddin S**, Ibrahim MI, Al Homsy U, Demime S. Pre-treatment serum profiling of immune mediators as predictive biomarkers of response in Non-Small cell lung cancer patients treated with anti-PD-1/PD-L1. **Frontiers of Immunology; 14:1157100, 2023.**
47. Shoaib S, Khan FB, Alsharif MA, Malik MS, Ahmed SA, Jamou Y, **Uddin S**, Tan CS, Ardianto C, Tufail S, Ming ML, Yusuf N, Islam N. Prospective Pharmacological Potential of Isothiocyanates: Reviewing the Targeting of Various Signal Transduction pathways in Female-Specific Cancers. **Cancers 15:2390; 2023.**



48. Shaukat SN, Nasir F, Raza A, Khanani R, **Uddin S**, Kazmi SU. Expression profile of KIR3DS1/KIR3DL1 receptors in association with immunological responses in TB, HIV and HIV/TB infected patients. **Microbial pathogenesis 180:106145; 2023.**
49. Singh AV ,Chandrasekar V, , Jessy S, Prabhu, **Uddin S**, Dakua SK. Maternal exposure to endocrine disrupting chemicals: correlation with postpartum health, fetal outcomes and placental health. **Biomedicine & Pharmacotherapy :163:114784, 2023.**
50. Akhtar S, Alsayed RKM, Ahmed F, AlHammadi A, Al-Khawaga S, Sara AlHarami SAM, Alam MA, Naama KA, Buddenkotte J, **Uddin S**, Steinhoff M, Ahmad A. Epigenetic control of inflammation in Atopic Dermatitis. **Seminars in Cell and Developmental Biology ;S1084-9521(23)00100-3; 2023.**
51. Chauhan R, Gupta A, Malhotra L, Bhat AA, Pandita RK, Masoodi T, Dagar G, Sadida HQ, Marzooqi SK, Batra A, Bakhshi S, Sharma MC, Tanwar P, Khan SA, Samath EA, **Uddin S**, Akil MA, Haris M, Macha MA, Pandita TK, Singh M. Ubiquitin Specific Peptidase 37 and PCNA interaction promotes Osteosarcoma pathogenesis by modulating replication fork progression. **Journal Translational Medicine :21(1):286; 2023.**
52. Gupta A, Dagar G, Chauhan R, Sadida H, Almarzooqi S, Hashem S, **Uddin S**, Macha MA, Akil AA, Pandita TK, Bhat AA Singh M. Cyclin-dependent kinases in cancer; Role, regulation, and therapeutic targeting. **Advances in Protein Chemistry and Structural Biology (APCSB), 135:21-55, 2023.**
53. Alsayed RKME, Sheikhan KSAM, Alam MA, Buddenkotte J, Steinhoff M, **Uddin S**, Ahmad A. Epigenetic programming of cancer stemness by transcription factors-non-coding RNAs interactions. **Semin Cancer Biol. 2023 Apr 11;92:74-83.**
54. Khan SR, Scheffler M, Soomar SM, Rashid YA, Moosajee M, Ahmad A, Raza A, **Uddin S**. Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker. **Pathol Res Pract. 245:154455, 2023.**
55. Almaghrbi H, Elkardawy R, Kumar SU, Kuttikrishnan S, Abunada T, Ahmad A, **Uddin S**, Doss GP, Zayed H. Analysis of signaling cascades from myeloma cells treated with pristimerin. **Adv Protein Chem Struct Biol 134:147-174, 2023.**
56. Farzaneh M, Masoodi T, Ghaedrahmati F, Radoszkiewicz K, Anbiyaiee A, Rad KK, Sheykhi-Sabzehpoush M, **Uddin S**, Jooybari SPM, Khoshnam SE, Azizidoost S. An Updated Review of the Contribution of Long Noncoding RNA-NEAT1 to the Progression of Human Cancers Cells. Pathology - **Research and Practice 245:154380, 2023.**
57. Taib N, Merhi M, Inchakalody V, Mestiri S, Hydrose S, Makni-Maalej K, Raza A, Sahir F, Azizi F, Nizamuddin PB, Fernandes Q, Yoosuf ZSKM, Almoghrabi S, Al-Zaidan L, Shablak A, **Uddin S**, Maccalli C, Al Homsy MU, Dermime S. **J Transl Med. 21:235, 2023.**
58. Idoudi S, Bedhiafi T, Sahir F, Hijji Y, **Uddin S**, Merhi M, Dermime S, Billa N. Studies on anti-colon cancer potential of nanoformulations of curcumin and succinylated curcumin in mannosylated chitosan. **Int J Biol Macromol. 235:123827; 2023**

59. Farzaneh M, Nasrolahi A, Ghaedrahmati F, Masoodi T, Najafi S, Sheykhi- Sabzehpoush M, Radoszkiewicz K, **Uddin S**, Azizidoost S, Khoshnam SE. Potential roles of lncRNA-XIST/miRNAs/mRNAs in human cancer cells. **Clinical and Translational Oncology (PMID: 36853400) 2023.**
60. Inchakalody VP, Hydrose SP, Krishnankutty R, Merhi M, Therachiyi L, Nai VS, Elashi AA, Khan AQ, Taleb S, Raza A, Safira Z, Fernandes Q, Al-Zaidan L, Mestiri S, Taib N, Bedhiafi T, Moustafa D, Assami L, Maalej KM, Elkord E, Uddin S, Al Homsy U, Dermime S. The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-Aza-CdR). **European Journal of Pharmacology 945:175612 2023.**
61. Mestiri S, Merhi M, Inchakalody VP, Taib N, Smatti MK, Ahmad F, Raza A, Ali FH, Hydrose S, Fernandesv Q, Ansari AW, Sahir F, Al-Zaidan L, Jalis M, Ghouf M, Allahverdi N, Al Homsy MU, **Uddin S**, Jeremijenkov AM, Nimir M, Abu Raddad LJA, Abid FB, Zaqout ASS, Alfheid SR, Saqr HMS, Omrani AS, Hssain AA, Al Maslamani HM, Yassine HM, Dermime S. Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: a pilot study. **Frontiers Immunology 10.3389/fimmu.2023.1061255 2023.**
62. Akbar S, Raza, A, Mohsen R, Kanbour A, Qadri S, Parray A, Gul ARZ, Philip A, Vijayakumar S, Merhi M, Hydrose S, Inchakalody VP, Abdulla R, Abualainin W, AbuSirriya S, Al-Bozom I, **Uddin S**, Khan O, Mohamed IMZ, Al Homsy, U, Dermime S. Circulating exosomal immunoncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD1/PDL1 therapy in NSCLC patients. **Frontiers Immunology 13:1097117,2023.**
63. Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Maccalli C, Cherif H, **Uddin S**, Steinhoff M, Marincola FM, Dermime S. CAR-T, CAR-NK and CAR-M in the era of solid tumors treatment: Current challenges and emerged therapeutic advances. **Molecular Cancers 22:20, 2023.**
64. Sharma T, Nisar N, Masoodi T, Macha MA, **Uddin S**, Akil AA, Pandita TK, Singh M, Bhat AA. Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond. **Adv Protein Chem Struct 133, 85-114, 2023.**
65. Merhi M, Ahmad F, Taib N, Inchakalody V, **Uddin S**, Shablak A, Dermime S. The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update. **Seminars Cancer Biol. (PMID: 36621515) 2023.**
66. Khan FB, Singh P, **Uddin S**, Jamous YF, Ali SA, Abdullah A, **Uddin S**, Zia Q, Jena MK, Jena MK, Khan M, Owais M, Alam A, Huang CY, Chanukuppa V, Ardianto C, Ming LC, Alam W, Khan, Ayoub MA. Multifaceted Pharmacological Potentials of Curcumin, Genistein and Tanshinone IIA through Proteomic Approaches: An in-depth Review. **Cancers 15, 249.2023.**
67. Bedhiafi T, Idoudi S, Alhams A, Fernandez Q, Iqbal H, Basineni R, Merhi M, **Uddin S**, Dermime S, Billa N. Applications of Polydopaminic Nanomaterials in Mucosal Drug Delivery. **Journal of Controlled Release 353: 842–849, 2023.**
68. Saman H, Raza A, Patil K, **Uddin S**, Crnogorac-Jurcevic T. Non-invasive biomarkers for early lung cancer detection. **Cancers 14: 5782, 2022.**
69. Therachiyil L, Anand A, Azmi A, Maryam F, Bhat A, **Uddin S**. Role of RAS signaling in Ovarian Cancer. **F1000 Research, 11:1253, 2022.**

70. Al-Hujaily EM, Al-Sowayan BS, Alyousef Z, **Uddin S**, Alammari F. Recruiting Immunity for the Fight Against Colorectal Cancer; Current Status and Challenges. **IJMS 23, 13696, 2022.**
71. Khan FB, **Uddin S**, Palakott AR, Anwar I, Khan M, Owais M, Huang C-Y, Daddam JR, Maqsood S, Ayoub MA. Illuminating the molecular intricacies of exosomes and ncRNAs in cardiovascular diseases: Prospective therapeutic and biomarker potential. **Cells 11, 3664, 2022.**
72. Akhtar S, Zarif L, Kuttikrishnan S, Prabhu KS, Patil K, Abou-Saleh H, Merhi M, Dermime S, Bhat AA, **Uddin S**. Guggulsterone target High mobility group Box-1 through JAK/STAT pathway to induce apoptosis in multiple myeloma cell lines. **Cancers 14, 5621, 2022.**
73. Al-Tamimi M, Khan AQ, Anvar R, Ahmad F, Mateo J, Raza SS, Alam M, Buddenkotte J, Steinhoff M, **Uddin S**. Pristimerin mediated cell death in cutaneous squamous skin cancer cells via ROS- activated JNK signaling pathway. **Biomedicine Pharmacotherapy 156, 113950, 2022.**
74. Bhat A, Nisar S, Mukherjee S, Saha N, Yarravarapu N, Lone S, Masoodi T, Chauhan R, Bagga P, Akil A, **Uddin S**, Reddy R, Singh M, Macha M, Haris M. Complimenting CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics. **Journal Translational Medicine 20, 534, 2022.**
75. Steinhoff M, Alam M, Ahmad A, **Uddin S**, Buddenkotte J. Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and clinical outcomes. **Seminar Cancer Biol. (36372325) 2022.**
76. Fernandes Q, Mestiri1 S, Bedhiafi T, Raza A, Merhi M, Hydrose S, El-Ella DM, Inchakalody1, VP, **Uddin S**, Dermime S Vaccines and Immunotherapies against the Human Papillomavirus and Epstein-Barr Virus (Book Chapter) 2022.
77. Therachiyil L, Hussein OJ, **Uddin S**, Korashy HM. Regulation of the Aryl Hydrocarbon Receptor in Cancer and Cancer Stem Cells of Gynecological Malignancies: An Update on Signaling Pathways. **Seminar Cancer Biol. S1044- 579X(22)00207-3 (PMID-36252938) 2022.**
78. Nasrolahi A , Azizidoost S , Radoszkiewicz K , Najafi S, Ghaedrahmati F , Anbiyaae O, Khoshnam SE , Farzaneh M , **Uddin S** , Signaling pathways governing glioma cancer stem cells behavior. **Cellular Signalling (PMID: 36228964) 2022.**
79. Patil K, Sher G, Kuttikrishnan K, Alam M, Buddenkotte J, Ahmad A, Steinhoff M, **Uddin S**, Epigenetic landscape of cutaneous T-cell lymphoma: emphasis on JAK/STA signaling pathway. **Semin Cell Dev Biol (PMID: 36216715) 2022.**
80. Idoudi S, Hijji Y, Korashy H, **Uddin S**, Merhi M, Dermime S, Billa N. A novel approach of encapsulating curcumin and succinylated derivative in mannosylated-chitosan nanoparticles **Carbohydrate polymer 297; 120034, 2022.**
81. Farzaneh M, Ghasemian M, Ghaedrahmati F, Poodineh J, Najafi S, Masoodi T, Kurniawan D, **Uddin S**, Azizidoost S. Functional roles of lncRN- TUG1 in hepatocellular carcinoma. **Life Sciences: 308; 120974 ,2022.**

82. Khan AQ, Agha MV, Shekhan K, Younis MH, Al-Tamimi M, Alam M, Ahmed A, **Uddin S**, Buddenkotte J, Steinhoff M. Targeting deregulated oxidative stress in skin inflammatory diseases: An update on clinical importance. **Biomedicine Pharmacotherapy 154:113601; 2022.**
83. Nisar S, Masoodi T, Prabhu K, Kuttikrishnan S, Zarif L, Khatoon S, Ali S, **Uddin S**, Akil AA, Singh M, Macha MA, Bhat AA. Natural Products as Chemo-Radiation Therapy Sensitizers in Cancers. **Biomedicine Pharmacotherapy. (PMID36030591) 2022.**
84. Azizidoost S, Ghaedrahmativ F, Sheykhi-Sabzehpoush M, **Uddin S**, Ghafourian M, Salehi AM, Keivan M, Cheraghzadeh M, Nazeri Z, Farzaneh M, Khoshnam SE. The Role of LncRNA MCM3AP-AS1 in Human Cancer. **Clinical and Translational Oncology PMID:36002764, 2022.**
85. Sher G, Patil K, Masoodi T, Akhtar S, Kuttikrishnan S, Ahmad A, **Uddin S**. Deregulated FOXM1 Signaling in regulation of Cancer Stem Cells: Therapeutic Challenges. **Seminar Cancer Biol. PMID: 35931301, 2022.**
86. Khan FB, Ansari MA, **Uddin S**, Palakott AR, Anwar I, Almatroudi A, Alomary MN, Alrumaihi F, Alkhay FF, Alghamdi S, Muhammad K, Huang CY, Daddam JR, Khan H, Maqsood S, Ayoub MA. . Bio-functional properties of Camel milk components: A Prospective role of bioactive molecules and exosomes in the therapeutic potential of camel milk against human diseases: An updated perspective. **Life 12, 990 :2022.**
87. Kuttikrishnan S, Masoodi M, Sher G, Bhat AA, Patil K, El-Elimat T, Oberlies NH, Pearce CJ, Haris M, Ahmad A, Alali FQ, Uddin S. Bioinformatics analysis reveals FOXM1/BUB1B signaling pathway as a key target of Neosetophomone B in human leukemic cells: A gene network-based microarray analysis. **Front. Oncol. PMID: 35847923, DOI: 10.3389/fonc.2022.929996.**
88. Bhat AA, Nisar S, Singh M, Ashraf B, Masoodi T, Prasad CP, Sharma A, Maacha S, Karedath K, Hashem S, Yasin SB, Bagga P, Reddy R, **Uddin S**, Dhawan P, Haris M, Macha MA. Cytokine and Chemokine Induced Inflammatory Colorectal Tumor Microenvironment: Emerging Avenue for Targeted Therapy. **Cancer Communications :10.1002/cac2.12295, 2022.**
89. Therachiyil L, Krishnankutty R, Ahmed F, Mateo JM, **Uddin S**, Korashy HM. Aryl hydrocarbon Receptor Promotes Cell Growth, Stemness Like Characteristics, and Metastasis in Ovarian Cancer via Activation of PI3K/Akt,  $\beta$ -Catenin Pathway and Epithelial to Mesenchymal Transition. **IJMS: 23, 6395; 2022.**
90. Hashem S, Ali TA, Akhtar S, Nisar S, Sageena G, Ali S, Al-Mannai S, Therachiyil L, Mir R, Elfaki I, Mir MM, Jamal F, **Uddin S**, Singh, M, Haris M, Macha M, Bhat AA, Targeting Novel cancer signaling Crosstalks by Natural Products: Avenues for inhibiting carcinogenesis. **Biomedicine Pharmacotherapy, 150: 2022.**
91. Sharma T, Gupta A, Chauhan R, Bhat AA, Nisar S, Hashem S, Akhtar S, Ahmad A, Haris M, Singh M, **Uddin S**. Cross-talk between the microbiome and chronic inflammation in esophageal cancer; Potential driver of oncogenesis. Cancer and **Metastasis Review , 150:1130542022.**

92. Alsayed RKME, Khan AQ, Ahmad F, Ansari AW, Alam MA, Buddenkotte J, Steinhoff M, **Uddin S**, Ahmad A. Epigenetic Regulation of CXCR4 Signaling in Cancer Pathogenesis and Progression. **Semin Cancer Biol . 25:S1044, 2022.**
93. Raza A, Khan AQ, Inchakalody VP, Mestiri S, Safira Z, Bedhiafi T, El-Ella DM, Taib N, Hydrose H, Akbar S, Fernandes Q, Al-Zaidan L, Krishnankutty R, Merhi M, **Uddin S**, Dermime S. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer **J Exp Clin Cancer Res 41:99,2022.**
94. Kuttikrishnan S, Bhat AA, Mateo J, Ahmad F, AlAai FQ, El-Elimat T, Oberlies NH, Pearce CJ7, **Uddin S**. Anticancer activity of Neosetophomone B by targeting AKT/SKP2/MTH1 axis in leukemic cells. **Biochem Biophys Res Commun; 601, 59-64, 2022.**
95. Fernandes F, Inchakalody VP, Merhi M, Mestiri S, Taib N, El-Ella DMA, Bedhiafi T, Raza A, Al-Zaidan L, Mohsen M, Al-Nesf MAY, Hssain AA, Yassine YH, Bachmann MF, **Uddin S**, Dermime S. Emerging COVID-19 Variants and their Impact on SARS-CoV-2 Diagnosis, Therapeutics and Vaccines. **Ann Medicine: 54, 524- 540, 2022.**
96. Moustafa R, Prabhu KS, Stewart D, Ryan C, AbdelAziz H, EL Edrisi M, Izham M, **Uddin S**, Tonna A. The incidence of metabolic syndrome amongst Qatar migrants 24 months post-migration: A prospective longitudinal observational cohort study. **Journal of Clinical Medicine: 11; 34;2022.**
97. Ahmad R, Riaz M, Aldholmi M, Qureshi MA, **Uddin S**, Bhat AA, Poyil P, Baig M, Pourahmad J, Ganesan T, Khan AQ, Siddiqui Z, El-Demellawy M, Gholamalizadeh M, Purnomosari D, Salim EI, Mousavi Jarrahi SZ, Zhang JY, Mohammad Nejad S, Mosavi Jarrahi A. Development of a Critical Appraisal Tool (AIMRDA) for the Peer- Review of Studies Assessing the In Vitro Anticancer Activity of Natural Products: A Step Towards Reproducibility. **Asian Pac J Cancer Prev. 2;22(12):3735-3740,2022.**
98. Ahmad A, Poltronieri P, **Uddin S**. Editorial: IncRNAs in Cancer Metastasis and Therapy Resistance. **Front. Oncol.: DOI: 10.3389/fonc.2021.813274:(2021).**
99. Bedhiafi T, Inchakalody VP, Fernandes Q, Mestiri S, **Uddin S**, Merhi M. Dermime S. The potential role of vitamin C in empowering cancer immunotherapy. **Biomedicine Pharmacotherapy: 146:112553:2021.**
100. Patil K, Kuttikrishnan S, Khan AQ, Ahmad F, Alam M, Buddenkotte, J, Ahmad A, Steinhoff M, **Uddin S**. Role of chemokines/ cytokines dysregulated signaling pathways in cutaneous T-cell lymphoma. **Semin in Cancer Biology (PMID 34906723) 2021.**
101. Prabhu KS, Siveen KS, Kuttikrishnan S, Raza SS, Raheed, Jochebeth A, Khan AQ, Bhat AA, Haris M, Kulinski M, Dermime S, Steinhoff M, **Uddin S**. Sanguinarine inhibits the growth of human NSCLC and cancer stem cells through downregulation of JAK/STAT pathway in vitro and in vivo. **Biomedicine Pharmacotherapy 144: 112358, 2021.**
102. Kuttikrishnan S, Prabhu KS, Al Sharie AH, Al Zu'bi Y, Alali FQ, Ahmad A, El-Elimat T, **Uddin S**. Natural Antitumor Resorcylic Acid Lactones: A Chemical Biology Approach. **Drug Discovery Today PMID: 34655796 : 2021.**

103. Ahmad S, Abbas M, Ullah MF, Aziz MH; Beylerli O, Alam MA, Syed MA, **Uddin S**, Ahmad A. Long non-coding RNAs Regulated NF- $\kappa$ B Signaling in Cancer Metastasis: Micromanaging by Not So Small Non-coding RNAs. **Seminar Cancer Biology 24:S1044-579X(21)00210-8 ;2021.**
104. Khan AQ, Rashid K, AlAmodi AA, Agha MV, Akhtar S, Hakeem I, Raza S, **Uddin S**. Role of ROS in benzophenanthridine alkaloids mediated anti-cancer activity. Biomedicine Pharmacotherapy. PMID: 34536761: 2021
105. Rahman M U A, Prabhu KS , Raza A, Elmi M, Mahmood N, Shah H, Abid FB, Dermime S, **Uddin S**, Izham MI. Biological markers and radiological parameters in COVID-19 positive healthcare workers in government hospitals, Qatar. **Journal of Translational Science doi: 10.15761/JTS.1000464 (2021).**
106. Patil K, Akhtar S, Khan FB, Ahmad A, **Uddin S**. Role of cancer stem cells in pancreatic cancer resistance. **Cancer Metastasis Review (PMID: 34453639) 2021.**
107. Kuttikrishnan S, Prabhu SK, Khan AQ, Alali FQ, Ahmad A, **Uddin S**. Targeting of FoxM1 and its associated signaling in B-precursor acute lymphoblastic leukemia. **Leukemia Lymphoma 9:1-11;2021.**
108. Khan AQ, Al-Tamimi M, **Uddin S**, Steinhoff M. F-box proteins in cancer stemness: an emerging prognostic and therapeutic target. **Drug Discovery Today 12:S1359- 6446(21)00314-7:2021.**
109. Al-Zaidan L, Merhi M, Raza A, Mestiri S, Inchakalody V, Fernandes Q, Taib N, **Uddin S**, Dermime. SARS-CoV-2 S protein binding hACE2: viral entry, pathogenesis, prognosis, and potential therapeutic targets. **Tumor Biology 43:177-196 ; 2021.**
110. Naija A, Merhi M, Inchakalody V, Fernandes Q, Mestiri S, Prabhu K, **Uddin S**, Dermime S. The role of PAK4 on the immune system and its potential implication in cancer immunotherapy. **Cellular Immunology 367, 104408 , 2021.**
111. Osman S, Raza A, Al-Zaidan L, Philipose V; Abdelaziz N, Merhi M, Prabhu KS, Hydrose S, **Uddin S**, Dermime S. **Biomedicine & Pharmacotherapy 141:111844, 2021.**
112. Gibreel S, Prabhu KS, **Uddin S**, Spencer AJ, Ha D, Do LG, Al Thani M, Al Khateb A, Al Mannai G. Urinary fluoride excretion among children in Qatar. **Ann Pediatr Child Health 9(5): 1239:2021.**
113. Nisar S, Bhat AB, Singh M, Karedath T, Rizwan A, Hashem S, Bagga P, Reddy R, Jamal F, **Uddin S**, Chand G, El-Rifai W, Frenneaux MP, Macha MA, Ahmed I, Haris, M. **Frontiers in Cell and Developmental Biology: 9:617281: 2021.**
114. Rahman M U A, Prabhu KS , Raza A, Elmi M, Mahmood N, Shah H, Abid FB, Dermime S, **Uddin S**, Izham MI. Biological markers and radiological parameters in COVID-19 positive healthcare workers in government hospitals, Qatar. Journal of Translational Science doi: 10.15761/JTS.1000464 (2021).
115. Relecom A, Merhi M, Inchakalody V, **Uddin S**, Rinchai D, Bedognetti D, Dermime S. Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. **J. Exp Clin Cancer Res. 40:74: 2021.**

116. Khan AQ, **Uddin S**. Anticancer Activity of Natural Compounds. **Asian Pac J Cancer Prev. 21S2:1-2: 2021.**
117. Bhat AA, Nisar S, Maacha S, Carneiro-Lobo T, Akhtar S, Siveen KS, Wani N, Rizwan A, Bagga P, Singh M, Reddy R, **Uddin S**, Grivel J, Chand G, Frenneaux M, Siddiqi MA, Bedognetti D, El-Rifai W, Macha MA, Haris M. Cytokine- Chemokine Network Driven Metastasis in Esophageal Cancer; Promising Avenue for Targeted Therapy. **Molecular Cancer 4:20: 2021.**
118. Siveen KS, Nizamuddin PB, **Uddin S**, Al-Thani M, Frenneaux MP, Janahi I, Steinhoff M, Azizi F. TRPV2: A Cancer Biomarker and Potential Therapeutic Target. **Disease Markers doi: 10.1155/2020/8892312. eCollection 2020.**
119. Khan AQ, Akhtar S, Prabhu KS, Zarif L, Khan R, Allam M, Buddenkotte, Ahmad A, Steinhoff M, **Uddin S**. Exosomes: An emerging therapeutic target to treat cancer using biologically active natural products. **Int J Mol Sci. 21, 9264, 2020.**
120. Saman H, **Uddin S**, Raza SS, Shrimali R, Rasul K. Understanding checkpoint inhibitors in cancer therapy, mechanisms of action, resistance and future challenges **Journal Clinical Oncology and Research: DOI: 10.31487/j.COR.2020.09.08: 2020.**
121. Khan AQ, Rashid K, AlAmodi AA, Raza SS, **Uddin S**. Recent developments in unraveling signaling mechanisms underlying cancer resistance due to cancer stem like cells. **Current Opinion in Pharmacology : 54:130-141 2020.**
122. Therachiyil L, Haroon J, Shahir F, Siveen KS, **Uddin S**, Buddenkotte J, Steinhoff M, Krishnankutty R. Dysregulated phosphorylation of mutant p53, autophagy and stemness attributes to the impaired sensitivity of colon cancer cells to oxaliplatin. **Front Oncol: 10:1744;2020.**
123. Merhi M, Raza A, Inchakalody VP, Siveen KS, Kumar D, Panayampilly F, Mestiri S, Hydrose SP, Allahverdi N, Jalis M, Relecom A, Zaidan L, Hamid M, Mostafa M, Gul AR, **Uddin S**, Homsy M, Dermime S. Persistent anti-NY-ESO-1 specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radio-immunotherapy treatment: a case report. **J. Immunotherap. Cancer: 8: e001278; 2020.**
124. Akhtar S, Therachiyil L, Shireen H, Agouni, A, Zeidan A, **Uddin S**, . Korashy H- Mechanisms of the Epigenetic Regulation of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway **Seminar in Cancer Biology: 83:177-196;2022.**
125. Sher G, Salman NA, Khan AQ, Prabhu KS, Raza F, Kulinski M, Dermime S, Haris M, Junejo K, **Uddin S**. Epigenetic and Breast Cancer: Promises and Therapeutic applications. **Seminar in Cancer Biology: 83:152-165; 2020.**
126. Riaz S, Abdulrahman N, **Uddin S**, Jabeena A, Gadeau AP, Fliegel L, Mraiche F. Anti-hypertrophic Effect of Na<sup>+</sup>/H<sup>+</sup> Exchanger-1 Inhibition Is Mediated by Reduced Cathepsin B. **Eur J Pharmacol. 888:173420; 2020.**
127. Khan AQ, Ahmad F, Raza SS, Zarif L, Siveen KS, Sher G, Agha M, Rashid K, Kulinski M, Buddenkotte J, **Uddin S**, Steinhoff M. Role of Non-coding RNA and RNA modifiers in the progression and resistance of cutaneous malignancies and autoimmune diseases. **Seminar in Cancer Biology 2020 (accepted).**

128. Akhtar S, Ali TA, Faiyaz A, Khan OS, Kulinski M, Omri HE, Bhat A, **Uddin S**. Cytokines mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma. **Int J Mol Sci. 21:E5002 2020.**
129. Nabeel A, Sveen KS, Jensa A, Huseyin Y, Hasan A, **Uddin S**, Mraiche, F Inhibition of p90 Ribosomal S6 Kinase Potentiates Cisplatin Activity in A549 Human Lung Adenocarcinoma Cells. **Journal of Pharmacy and Pharmacology; 72:1536-1545; 2020.**
130. Nisar S, Bhat AA, Hashem Syed N, Yadav SK, **Uddin S**, Fakhro K, Bagga P, Thompson PM, Reddy R, Frenneaux MP, Haris M. Brain changes Associate with Genetic changes in Post-Traumatic Stress Disorder. **IJMS 21:4503 ;2020.**
131. Sher G, Salman NA, Kulinski M, Gupta VK, Fadel RA, Anand A, Gehani S, Ahmad A, Al-Yahri O, Shahid F, Davies G, Dermime D, **Uddin S**, Ashrafi H, Junejo K. An investigation on the association of high-risk human papillomavirus (HPV) types with Breast Cancer in the population of Qatar. **Cancer 10:12(6):E1528 2020.**
132. Ahmad A, **Uddin S**, Steinhoff M, CAR-T Cell Therapy: The Story So Far. **IJMS 21: E3906, 2020.**
133. Saman H, Raza SS, **Uddin S**, Rasul K. Inducing Angiogenesis, a Hall Marks of Cancer, and Treatment Approaches. **Cancer 12. pii: E1172, 2020.**
134. Hashem S, Nisar S, Sageena G, Yadav S, Krishnakutty R, Macha MA, **Uddin S**, Haris M, Bhat AA. Curcumol; Structure, Synthesis, and Biological Activities. **Nutr Cancer. 14:1-15.**
135. Haris M, Nisar S, Hashem S, Bhat AA, Yadav S, Shanmugakonar M, Al-Naemi H, Bagga P, **Uddin S**, Reddy R. Functional In Vivo Imaging of Tumors. **Cancer Treat Res. 180:3-50, 2020.**
136. Raza A, Merhi M, Inchakalody VP, Krishnankutty R, Relecom A, **Uddin S**, Dermime S. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. **J Trans Med. 18:140, 2020.**
137. Khan AQ, Mohamed EN, Hakeem I, Nazeer A, Kuttikrishnan S, Prabhu KS, Nawaz Z, Ahmad A, Zayed H, **Uddin S**. Sanguinarine induces apoptosis in papillary thyroid cancer cells via generation of reactive oxygen species **Molecules 25. pii: E1229, 2020.**
138. Bhat AA, Younes SN, Raza S, Zarif L, Nisar S, Mir R, Kumar S, Sharawal SK, Heshem S, Elfaki I, Ahmed A, Kulinski M, Zayed H, Haris M, **Uddin S**. Role of non- coding RNA networks in leukemia progression, metastases and drug resistance. **Molecular Cancer 19:57, 2020.**
139. Abbas TO, Ali TA, **Uddin S**, Urine as a Main Effector in Urological Tissue Engineering; A Double-Sided Sword. **Cells. 26;9(3). pii: E538, 2020.**
140. Prabhu K, Raza A, Karedath T, Raza SS, Ahmed EI, Kuttikrishnan S, Therachiyil L, Kulinski M, Dermine S, Junejo K, Steinhoff M, **Uddin S**. Non-coding RNAs as regulators and markers of targeting in breast cancer and breast cancer stem cells. **Cancer (Basel)12. pii: E351,2020.**
141. Bhat AA, Syed N, Therachiyil L, Nisar S, Hashem S, Krishnankuty R, Macha MA, Yadav SK, Bagga P, Reddy R, Shanmagaonkar M, Al-Naemi H, Dhawan P, **Uddin S**, El-Rifai W,



- Mohammad Haris. Claudin-1 and Cancer; Tumor Promoter or Suppressor, A Pendulum That Swings Both Sides. **Int J Mol Sci. 21. pii: E569, 2020.**
142. Khan AQ, Ahmed EA, Elareer NR, Prabhu KS, Siveen KS, Kulinski M, Ahmad A, Steinhoff M, **Uddin S**. Curcumin-mediated apoptotic cell death in papillary thyroid cancer and cancer stem-like cells through targeting of JAK/STAT3 signaling pathway. **Int J Mol Sci;21(2). pii: E438, 2020.**
  143. Younes N, Younes S, Alsharabasi OA, El Zowalaty ME, Mustafa I, Jahromi M, **Uddin S**, Al-Nesf M, Pintus G, Zayed H. Immunogenetics of Celiac Disease: A Focus on Arab Countries. **Current Molecular Medicine ; 20(4):275-285;2020.**
  144. Nisar S, Hashem S, Bhat AA, Yadav S, Azeem MW, **Uddin S**, Bagga P, Reddy R, Haris M. Association of genes with phenotype in Autism spectrum disorder. **Aging Aging (Albany NY)11:10742-10770 2019.**
  145. Leo R, Therachiyil L, Siveen SK, **Uddin S**, Kulinski MA, Buddenkotte J, Steinhoff M, Krishnankutty R. Protein Expression Profiling Identifies Key Proteins and Pathways Involved in Growth Inhibitory effects Exerted by Guggulsterone in Human Colorectal Cancer Cells. **Cancers: 11. pii: E1478;2019.**
  146. Khan AQ, Ahmed EI, Elareer NE, Junejo K, Steinhoff M, **Uddin S**. Role of miRNA- regulated cancer stem cells in the pathogenesis of human malignancies. **Cells 8: 840. 2019.**
  147. Siveen KS, Raza A, Khan AQ, Prabhu KS, Kuttikrishnan S, Mateo JM, Zayed H, Rasul R, Dermime S, Steinhoff M, **Uddin S**. Role of extracellular vesicles in the development and progression of colorectal cancer. **Cancers (Basel)11: 746. 2019.**
  148. Kuttikrishnan S, Siveen KS, Prabhu KS, Khan AQ, Ahmed EI, Akhtar S, Ali TA, Merhi M, Dermime S, Steinhoff M, **Uddin S**. Curcumin induces mitochondrial apoptotic cell death via inhibition of PI3-Kinase/AKT pathway in B-precursor acute lymphoblastic leukemia. **Front in Oncol ;9: 484, 2019.**
  149. Merhi M, Raza A, Inchakalody V, Zar AR, **Uddin S**, Dermime S. Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma. **Ann Trans Med. 7: (Suppl 1):S22;2019.**
  150. Akhtar S, Achkar IW, Siveen KS, Kuttikrishnan S, Prabhu KS, Khan AQ, Ahmed EI, Sahir F,, Jerobin J, Raza A, Merhi M, Elsabah HM, Taha R, Omri HE, Zayed H, Dermime S, Steinhoff M, **Uddin S**. Sanguinarine induces apoptosis pathway in multiple myeloma cell lines via inhibition of the Jak2/STAT3 signaling. **Frontiers Oncol;9:285, 2019.**
  151. Prabhu KS, Siveen KS, Kuttikrishnan S, Jochebeth A, Ali TA, Elareer NR, Iskandarani A, Khan Q A, Merhi M, Dermime S, El-Elimat T, Oberlies NH, Alali FQ, Steinhoff M, **Uddin S**. Greensporone A, a Fungal Secondary Metabolite Suppressed Constitutively Activated AKT via ROS Generation and Induced Apoptosis in Leukemic Cell Lines. **Biomolecules. ;9:126; 2019.**
  152. Maacha S, Bhat AA, Jimenez L, Raza A, Haris M, **Uddin S**, Grivel J. Extracellular vesicles-mediated intercellular communication: Roles in the tumor microenvironment and anti-cancer drug resistance. **Molecular Cancer 18:55; 2019.**

153. Siveen KS, Prabhu KS , Parray A , Merhi M, Arredouani A, Chikri M, **Uddin S** , Dermime S , Mohammad R , Steinhoff M , Janahi I. Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation. **Sci Report 9:1554;2019.**
154. Achkar IW, Bhat AA, Zafar M, Abbas M, Khan OS, Kuttikrishnan S, Prabhu KS, **Uddin S**. Oncogenic role of deregulated leptin signaling in the pathogenesis of ovarian cancer. **Trans Medicine Comm. 4:1, 2019.**
155. Bhat A, Uppada JB, Achkar I, Hashem S, Yadav S, Shanmugakonar M, Al- Naemi HA, Haris H, **Uddin S**. Tight Junction Proteins and Signaling Pathways: A Functional Crosstalk. **Front Physiology 9:1942; 2018.**
156. Krishnankutty R, Iskandarani A, Therachiyil L, **Uddin S** , Azizi F, Kulinski M, Bhat A, Mohammad RM. Anticancer Activity of Camel Milk via Induction of Autophagic Death in Human Colorectal and Breast Cancer Cells. **Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3501-3509.**
157. Khan AQ, Siveen KS, Prabhu KS, Kuttikrishnan S, Akhtar S, Raza A, Mraiche F, Dermime S, **Uddin S**. Curcumin-mediated degradation of S-phase kinase protein 2 induces cytotoxic effects in human papillomavirus-positive and negative squamous carcinoma cells. . **Front Oncol; 8:399; 2018.**
158. Kuttikrishnan S, Siveen KS, Prabhu KS, Khan AQ, Akhtar S, Mateo JM, Merhi M, Taha R, Omri HE, Mraiche F, Dermime S, **Uddin S**. Sanguinarine suppresses growth and induces apoptosis in childhood acute lymphoblastic leukemia. **Leukemia Lymphoma; 60:782-794 2018.**
159. Merhi M , Raza A , Inchakalody VP , Nashwan AJ , Allahverdi N , Krishnankutty R , **Uddin S** , Gul ARZ, Al Homsy MU, Dermime S. Squamous cell carcinomas of the head and neck cancer' response to PD-1 targeting and differential expression of immunological markers. **Front Immunol; 9:1769; 2018.**
160. Prabhu KS, Siveen KS, Kuttikrishnan S, Iskandarani A, Khan AQ, Merhi M, Omri HE, Dermime S, Elimat T, Oberlies N, Ali F, **Uddin S**. Greensporone C, a freshwater fungal secondary metabolite-induces mitochondrial-mediated apoptotic cell death in leukemic cell lines. **Frontiers of Pharmacology;9:720. 2018.**
161. Fernandes Q, Merhi M, Raza A , Inchakalody VP, Abdelouahab N, Gul ARZ, **Uddin S**, Dermime S. Role of Epstein-Barr virus in Head and Neck Cancers: An Immunological Perspective. **Front oncol; 8:257; 2018.**
162. Halama A, Kulinski M, Dib SS, Zaghlool SB, Siveen KS, Iskandarani A,. Satheesh NJ, Bhagwat AM, **Uddin S**, Kastenmüller G, Elemento O, Gross5 SS Suhre K. Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis. **Cancer Lett. 2018:430:133-147.**
163. Achkar IW, Abdulrahman N, Al-Sulaiti H, Joseph JM, **Uddin S**, Mraiche F . Cisplatin Based Therapy: The Role of the Mitogen Activated Protein Kinase Signaling Pathway. **J. Translational Med. 2018: 16:96.**

164. Prabhu KS, Achkar IW, Kuttikrishnan S, Khan AQ, Siveen KS, **Uddin S**. Embelin; a benzoquinone possesses therapeutic potential for the treatment of human cancer. **Future Med Chemistry 2018;10:961-976.**
165. Khan AQ, Kuttikrishnan S, Siveen KS, Prabhu P, Shanmugakonar M, Al-Naemi HA, Haris M, Dermime S, **Uddin S**. RAS-mediated oncogenic signaling pathways in human malignancies. . **Seminar in Cancer Biology. 54:1-13;2018.**
166. Siveen KS, Prabhu KS, Achkar IW, Kuttikrishnan S, Shyam S, Khan AQ, Merhi M, Dermime S, **Uddin S**. Role of Non Receptor Tyrosine Kinases in Hematological Malignancies and its Targeting by Natural Products. **Mol Cancer. 2018;17(1):31.**
167. Kilunski M, Achkar IW, Haris M, Dermime S, Mohammad RM, **Uddin S**. Role of dysregulated expression of SKP2 in hematological malignancies. **Leukemia Lymphoma 2017: 10:1-13.**
168. Prabhu KS, Siveen KS, Kuttikrishnan S, Iskandarani A, Tsakou M, Therachiyil L, Krishnankutty R, Parray AS, Kilunski M, Merhi M, Dermime S, Mohammad RM, **Uddin S**. Targeting of X-Linked Inhibitor of Apoptosis Protein and PI3-kinase/AKT signaling suppresses growth and survival of leukemic cells. **PlosOne 2017: 12:e0180895.**
169. Achkar IW, MraicheF, Mohammad RM, **Uddin S**. Anticancer potential of Sanguinarine for various human malignancies. **Future Med Chemistry 2017 :9:933-950.**
170. Bhat AA, Prabhu KS, Kuttikrishnan S, Krishnankutty R, Mohammad RM, **Uddin S**. Potential therapeutic targets of Guggulsterone in cancer. **Nutrition and Metabolism 2017 14:23.**
171. Siveen KS, **Uddin S**, Mohammad RM. Targeting acute myeloid leukemia stem cell signaling by natural products. **Molecular Cancer 2017: 16:13.**
172. Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali F, Dermime S, Mohammad RM, **Uddin S**. Vascular endothelial growth factor (VEGF) signaling in tumor vascularization: Potential and Challenges. **Current Vascular Pharmacology 2017: 15:339-351.**
173. Krishnankutty R, Bhat AA, Azmi AS, Souchelnytskyi S, **Uddin S**, Abou-Samra AB, Mohammad RM. An Overview of Proteomics Techniques and its Application as a Tool in Biomarker and Drug Discovery. **Proteomics Enzymol 2016, 5:2.**
174. Khan OS, Bhat AA, Krishnankutty R, Mohammad RM, **Uddin. S**. Therapeutic potential of resveratrol in lymphoid malignancies. **Nutrition and Cancer 2016:68:365-73.**
175. Iskandarani A, , Bhat AA, Siveen KS, Prabhu KS, Kuttikrishnan S, Khan KM, Krishnankutty R, Kulinski M, Nasr RR, Mohammad RM, **Uddin S**. Bortezomib- mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. **J. Translational Med. 2016:14:69.**
176. **Uddin S**, Bhat AA, Krishnankutty R, Mir F, Kulinski M, Mohammad RM. Involvement of F-box proteins in human malignancies. **Seminar in Cancer Biology. 2016: 36:18-32.**
177. **Uddin S**, Mohammad RM. Role of Leptin and Leptin receptors in hematological malignancies. **Leukemia Lymphoma 2016: 57:10-6.**

178. Bhat AA, **Uddin S**. Notch signaling in colon cancer: Road less traveled. **Oncobiol Targets 2015;2:1-3.**
179. Beg S, Siraj AK, Prabhakaran S, Bu R, Al-Rasheed M, Sultana M, Qadri Z, Al- Assiri M, Sairafi R, Al-Dayel F, Al-Sanea N, **Uddin S**, Al-Kuraya KS. Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. **Cancer. 2015: 21:3799-808.**
180. Ahmed M, Hussain AR, Siraj AK, **Uddin S**, Al-Sanea N, Al-Dayel F, Al-Assiri M, Beg S, Al-Kuraya KS Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. **Mol Cancer. 2015;14:131.**
181. Hussain AR, Al-Romaizan M, Ahmed M, Thangavel S, Al-Dayel F, Beg S, **Uddin S**, Siraj AK, Al-Kuraya KS. Dual Targeting of mTOR Activity with Torin2 Potentiates Anti-Cancer Effects of Cisplatin in Epithelial Ovarian Cancer. **Mol Med. 2015: 21:466-78.**
182. Hussain AR, Bu R, Ahmed M, Jehan Z, Beg S, Al-Sobhi S, Al-Dayel F, Siraj AK, **Uddin S**, Al-Kuraya KS. Role of X-Linked Inhibitor of Apoptosis as a prognostic marker and therapeutic target in Papillary Thyroid Carcinoma. **J Clin Endocrinol Metab. 2015: 100:E974-85.**
183. Siraj AK, Prabhakaran S, Bavi P, Bu R, Beg S, Hazmi MA, Al-Rasheed M, Al- Assiri M, Sairafi R, Al-Dayel F, Al-Sanea N, **Uddin S**, Al-Kuraya KS. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer. **Cancer. 2015: 121:1762-71.**
184. Siraj A, Bu R, Prabhakaran S, Bavi P, Beg S, Al-Hazmi M, Al-Rasheed M, Al- Sania N, Dayel F, **Uddin S**, Al-Kuraya KS. A Very Low Incidence of BRAF Mutations In Middle Eastern Colorectal Carcinoma. **Molecular Cancer: 2014; 13:168.**
185. **Uddin S**, Hussain AR, Khan OS, Al-Kuraya KS. Leptin receptor expression and colorectal carcinogenesis. **Tumor Biology 2014: 35:871-9.**
186. Ahmad M, Hussain AR, Bavi P, Ahmed SO, AlSobhiSF, Al-Dayel F, **Uddin S**, Al- Kuraya KS, High Prevalence of mTOR Complex Activity can be targeted using Torin2 in Papillary Thyroid Carcinoma. **Carcinogenesis 2014; 35:1564-72.**
187. Bu R, Hussain AR, Ahmed M, Al-Obaisi KAS, **Uddin S**, Al-Kuraya KS. Bortezomib inhibits proteasoma degradation of I $\kappa$ B $\alpha$  and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B cell lymphoma. **Leuk Lymph 2013;55:415-424.**
188. Bavi P, Jehan Z, Bu R, Prabhakaran S, Al-Sanea N, Al-Dayel F, Al-Assiri, M, Al- Halouly T, Sairafi R, **Uddin S**, and Al-Kuraya KS. ALK Gene Amplification Is Associated With Poor Prognosis In Colorectal Carcinoma. **British J Cancer 2013; 109: 2035-2043.**
189. Bu R, Siraj AK, Bavi P, Belgaumi A, Al-Haqawi W, Al-Dayel F, **Uddin S**, F. Alkuraya FS, Al-Kuraya KS. Constitutional Mismatch Repair-Deficiency Syndrome is a Rare Cause of Cancer Even in a Highly Consanguineous Population. **J cancer Ther 2013: 4, 996-1004.**
190. Hussain AR, **Uddin S**, Ahmed M, Al-Dayel F, Bavi P, Al-Kuraya KS. Phosphorylated I $\kappa$ B $\alpha$  predicts poor prognosis in Activated B-cell lymphoma and its inhibition with Thymoquinone induces apoptosis via ROS release. **PloS One 2013;8:e60540.**

191. Geslain R, **Uddin S**. Liu H, Jiang H, van Besien K, Pan, Wickrema A. Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. **Cytokine 2013;61, 329- 335.**
192. Bu R, Bavi P, Abubaker J, Jehan Z, Al-Haqavi W, **Uddin S** , Al-Kuraya KS. Role of NF- $\kappa$ B regulators-TNFAIP3 and CARD11 in Middle Eastern Diffuse Large B cell lymphoma. **Leuk Lymph2012; 53:1971-7.**
193. **Uddin S**, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, Bavi P, Al-Kuraya KS. Over-expression of FoxM1 offers a promising therapeutic target in diffuse large B- cell lymphoma. **Haematologica2012 ; 97:1092-100.**
194. Siraj AK, Khalak H, Sultana M, Al-Rasheed M, Bavi P, , Al-Sanea N , Al-Dayel F , **Uddin S**, Alkuraya FS, Al-Kuraya KS. Colorectal Cancer Risk Is Not Associated with Increased Levels of Homozygosity in Saudi Arabia. **Genetic in Medicine 2012; 14: 720–728.**
195. Bu R, **Uddin S**, (Joint First Author) Ahmed M, Hussain AR, Alsobhi S, Amin T, Al- Nuaim A, Al-Dayel F, Abubaker J, Bavi P, Al-Kuraya KS. c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce Papillary Thyroid Carcinoma cell death. **Mol Med. 2012 18:167-77.**
196. Hussain AR, Ahmed SO, Ahmed M, Khan OS, Plataniias LC, Al-Kuraya KS, **Uddin S**. Cross-talk between NF $\kappa$ B and the PI3-kinase/AKT pathway can be targeted in Primary Effusion Lymphoma (PEL) cell lines for efficient apoptosis. **PLoS One 2012: 7(6):e39945.**
197. Jehan Z, **Uddin S**, Al-Kuraya KS. In-situ hybridization as a molecular tool in cancer diagnosis and treatment. **Current Med Chem 2012; 19:3730-8.**
198. Ahmed M, **Uddin S**, Hussain A, Alyan A, Jehan Z, Al-Dayel F, Al-Nuaim A, Al- Sobhi S, Amin T, Bavi P, Al-Kuraya KS. FoxM1 and Its Association with Matrix Metalloproteinases (MMPs) Signaling Pathway in Papillary Thyroid Carcinoma. **Journal of Clin Endocrin Metab : 2012 97:E1-E13 .**
199. **Uddin S**, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. **Am J Pathol. 2011;179:3032-44.**
200. Bavi P, Bu R, **Uddin S**, Al-Kuraya KS. MMP7 Polymorphisms - A New Tool in Molecular Pathology to Understand Esophageal Cancer. **The Saudi Journal of Gastroenterology . 2011;17:299-300.**
201. Bavi P, Abubaker J, Al-Sanea N, Abuljabbar, Ashari LH, Al-Dayel F, **Uddin S**, Siraj AK, Al-Kuraya KS. Clinico-pathological significance of A20 alpha induced protein3 (TNFAIP3) in Middle Eastern colorectal carcinoma. **Clinical Epigenetics 2011;2:417-418.**
202. **Uddin S**, Al-Kuraya KS. Localization of death receptor 4 in lipid rafts sensitizes chronic lymphocytic leukemia to chemotherapeutic drug mediated apoptosis. **Leuk Lymphoma. 2011;52:1176-7.**
203. Bavi P, **Uddin S**, Bu R, Ahmed M, Abubaker J, Balde V, Qadri Z, Ajarim D, Al- Dayel F, Hussain AR, Al-Kuraya KS. The biological and clinical impact of inhibition of NF- $\kappa$ B-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). **J Pathol. 2011;224:355-66.**

204. Bavi P, **Uddin S**, Ahmed M, Jehan Z, Bu R, Abubaker J, Sultana M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Prabhakaran S, Hussain AR, Al-Kuraya KS. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. **Am J Pathol. 2011;178:2109-20.**
205. Hussain AR, Ahmed M, Ahmed S, Manogaran P, Plataniias LC, Alvi SN, Al- Kuraya KS, KS, **Uddin S**. Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma. **Free Radic Biol Med. 2011;50:978-87.**
206. **Uddin S**, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK, Al-Kuraya KS. Genome- wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. **Am J Pathol. 2011;178:537-47.**
207. **Uddin S**, Hussain AR, Siraj AK, Khan OS, Bavi PP, Al-Kuraya KS. Role of leptin and its receptors in the pathogenesis of thyroid cancer. **Int J Clin Exp Pathol. 2011;4:637-43.**
208. Hussain AR, **Uddin S**, Ahmed M, Ahmed SO, Al-Kuraya KS. Resveratrol suppresses constitutive activation of AKT via generation of reactive oxygen species and induces apoptosis in diffuse large B cell lymphoma cell lines. **PloS One 2011;6:e24703.**
209. Bu R, **Uddin S**, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, Ahmed M, Al- Kuraya KS. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. **Lab Invest. 2011;91:124-37.**
210. Siraj AK, Hussain AR, Al-Rasheed M, Ahmed M, Bavi P, Alsobhi SA, Al-Nuaim A, **Uddin S**, Al-Kuraya K. Demethylation of TMS1 gene sensitizes thyroid cancer cells to TRAIL-induced apoptosis. **J Clin Endocrinol Metab. 2011;96:E215-24.**
211. **Uddin S**, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, Bavi P, Al-Kuraya KS. Over Expression of Fatty Acid Synthase in Middle Eastern Epithelial Ovarian Carcinoma Activates AKT and its Inhibition Potentiates Cisplatin Induced Apoptosis. **Mol Med. 2011 Mar 21.**
212. Hussain AR, **Uddin S**, Ahmed M, Bu R, Ahmed SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, Al-Kuraya KS. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. **J Pathol. 2010;222:180-90.**
213. **Uddin S**, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P, Al-Kuraya KS. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. **Lab Invest. 2010 S;90:1346-56.**
214. Bavi P, Prabhakaran SE, Abubaker J, Qadri Z, George T, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, **Uddin S**, Al- Kuraya KS. Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. **Mol Cancer. 2010 30;9:203.**
215. **Uddin S**, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F, Bavi P, Al-kuraya KS. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. **Leuk Lymphoma. 2010 ;51:1305-14.**

216. **Uddin S**, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. **Mol Cancer Ther. 2010**;9:1244-55.
217. Hussain AR, Khan AS, Ahmed SO, Ahmed M, Plataniias LC, Al-Kuraya KS, **Uddin S**. Apigenin induces apoptosis via downregulation of S-phase kinase- associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells. **Cell Prolif. 2010;43:170-83.**
218. **Uddin S**, Bavi P, Siraj AK, Ahmed M, Al-Rasheed M, Hussain AR, Ahmed M, Amin T, Alzahrani A, Al-Dayel F, Abubaker J, Bu R, Al-Kuraya KS. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. **Endocr Relat Cancer. 2010** ;17:191-202.
219. **Uddin S**, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, Al-Kuraya KS, Munkarah A. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. **Int J Cancer. 2010** ;126:382-94.
220. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, **Uddin S**, Al-Kuraya KS. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. **J Pathol. 2009;219:435-45.**
221. **Uddin S**, Bavi PP, Hussain AR, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Ahmed M, Al-Kuraya KS. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. **Carcinogenesis. 2009;30:1832-40.**
222. Jehan Z, Bavi P, Sultana M, Abubaker J, Bu R, Hussain A, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, **Uddin S**, Al-Kuraya KS. Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. **J Pathol. 2009** 219:337-46.
223. **Uddin S**, Ahmed M, Hussain AR, Jehan Z, Al-Dayel F, Munkarah A, Bavi P, Al-Kuraya KS. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. **Lab Invest. 2009** ;89 :1115-27.
224. **Uddin S**, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P, Al-Kuraya KS. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. **Mol Cancer. 2009;18;8:74.**
225. Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, **Uddin S**, Al-Kuraya KS. PIK3CA alterations in Middle Eastern ovarian cancers. **Mol Cancer. 2009; 28;8:51.**
226. **Uddin S**, Hussain AR, Ahmed M, Abubaker J, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. **Am J Gastroenterol. 2009;104:1790-801.**
227. Hussain AR, Ahmed M, Ahmed SO, Al-Thari S, Khan AS, Razack S, Plataniias LC, Al-Kuraya KS, **Uddin S**. Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells. **Leuk Lymphoma. 2009;50:1204-13.**

228. Sassano A, Lo Iacono M, Antico G, Jordan A, **Uddin S**, Calogero RA, Plataniias LC. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. **Mol Cancer Ther. 2009;8:615-25.**
229. **Uddin S**, Khan AS, Al-Kuraya KS. Developing curcumin into a viable therapeutic for lymphoma. **Expert Opin Investig Drugs. 2009 ;18:57-67.**
230. **Uddin S**, Hussain A, Ahmed M, Belgaumi A, Al-Dayel F, Ajarim D, Bavi P, Al- Kuraya KS. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. **J Pathol. 2008;216:483-94.**
231. Zhou Y, **Uddin S**, Zimmerman T, Kang JA, Ulaszek J, Wickrema A. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. **Leuk Lymphoma. 2008;49:1945-53.**
232. **Uddin S**, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A, Al- Sobhi S, Al-Dayel F, Bavi P, Hussain AR, Al-Kuraya KS. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. **J Clin Endocrinol Metab. 2008 ;93:4088-97.**
233. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Plataniias LC, Al-Kuraya KS, **Uddin S**. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. **Mol Cancer Ther. 2008 ;7:3318-29.**
234. Siraj AK, Al-Rasheed M, Ibrahim M, Siddiqui K, Al-Dayel F, Al-Sanea O, **Uddin S**, Al-Kuraya K. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. **J Endocrinol Invest. 2008;31:893-9.**
235. Siraj AK, Ibrahim M, Al-Rasheed M, Abubaker J, Bu R, Siddiqui SU, Al-Dayel F, Al-Sanea O, Al-Nuaim A, **Uddin S**, Al-Kuraya K. Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. **BMC Med Genet. 2008 ;5:9:61.**
236. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, **Uddin S**, Al-Kuraya KS. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. **Oncogene. 2008 ;27:3539-45.**
237. Bavi P, Abubaker J, Hussain A, Sultana M, Al-Dayel F, **Uddin S**, Al-Kuraya KS. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. **Hum Pathol. 2008;39:885-94.**
238. **Uddin S**, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. **Cancer Res. 2008;68:3379-88.**
239. **Uddin S**, Plataniias LC. Sphingosine kinase is an attractive target for novel pharmacological interventions in non-Hodgkin lymphomas. **Leuk Lymphoma. 2008;49:850-1.**
240. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, **Uddin S**, Al-Kuraya KS. Clinicopathological analysis



of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. **J Clin Endocrinol Metab. 2008 ;93:611-8.**

241. Bavi PP, Abubaker JA, Jehan ZD, Al-Jomah NA, Siraj AK, Al-Harbi SR, Atizado VL, Abduljabbar AS, Alhomoud SJ, Ashari LH, Al-Dayel FH, **Uddin S**, Al-Kuraya KS, Alsanea NA. Colorectal carcinomas from Middle East. Molecular and tissue microarray analysis of genomic instability pathways. **Saudi Med J. 2008 ;29(1):75-80.**
242. Al-Dayel F, Al-Rasheed M, Ibrahim M, Bu R, Bavi P, Abubaker J, Al-Jomah N, Mohamed GH, Moorji A, **Uddin S**, Siraj AK, Al-Kuraya K. Polymorphisms of drug- metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. **Leuk Lymphoma. 2008 ;49:122-9.**
243. Jehan Z, Siraj AK, Abubaker J, Ruiz C, Simon R, Sultana M, **Uddin S**, Bavi P, Hussain A, Razack S, Ezzat A, Al-Dayel F, Sauter G, Al-Kuraya KS. Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma. **Oncology 2008;75:71-80.**
244. Siraj AK, Ibrahim M, Al-Rasheed M, Bu R, Bavi P, Jehan Z, Abubaker J, Murad W, Al-Dayel F, Ezzat A, El-Solh H, **Uddin S**, Al-Kuraya K. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. **Ann Hematol. 2007;86:887-95.**
245. Abubaker J, Bavi PP, Al-Harbi S, Siraj AK, Al-Dayel F, **Uddin S**, Al-Kuraya K. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. **Leukemia. 2007 ;21:2368-70.**
246. Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O, **Uddin S**, Al-Kuraya KS. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. **J Pathol. 2007;213:190-9.**
247. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, **Uddin S**, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R, Sauter G, Terracciano L, Tornillo L. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. **J Clin Pathol. 2007;60:768-72.**
248. Hussain AR, Al-Jomah NA, Siraj AK, Manogaran P, Al-Hussein K, Abubaker J, Plataniias LC, Al-Kuraya KS, **Uddin S**. Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. **Cancer Res. 2007;67:3888-97.**
249. Siddiqui SS, Siddiqui ZK, **Uddin S**, Minshall RD, Malik AB. p38 MAPK activation coupled to endocytosis is a determinant of endothelial monolayer integrity. **Am J Physiol Lung Cell Mol Physiol. 2006; 292:L114-24.**
250. **Uddin S**, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. **Blood. 2006;108:4178-86.**
251. Bavi P, Jehan Z, Atizado V, Al-Dossari H, Al-Dayel F, Tulbah A, Amr SS, Sheikh SS, Ezzat A, El-Solh H, **Uddin S**, Al-Kuraya K. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. **Cancer Epidemiol Biomarkers Prev. 2006;15:1708-18.**

252. **Uddin S**, Hussain AR, Al-Kuraya KS. JAK Family of Tyrosine Kinases: Its Functions and Alterations in Human Cancer. **Current Enzyme Inhibition. 2006; 2:163-171.**
253. Al-Kuraya KS, Bavi PP, Ezzat AA, Al-Dayel FA, **Uddin S**, Atizado VL, Al-Jomah NA, Amr SS, Sheikh SS, Sauter G, Simon R. Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. **Saudi Med J. 2006 ;27:323-8.**
254. Hussain AR, Al-Rasheed M, Manogaran PS, Al-Hussein KA, Platanius LC, Al Kuraya K, **Uddin S**. Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. **Apoptosis. 2006;11:245-54.**
255. **Uddin S**. Molecular Mechanisms of curcumin-induced apoptosis in lymphoid malignant cells. **Emirates Medical Journal . 2006; 24:37-45.**
256. Kaur S, **Uddin S**, Platanius LC. The PI3' kinase pathway in interferon signaling. **J Interferon Cytokine Res. 2005;25:780-7.**
257. **Uddin S**, Hussain AR, Manogaran PS, Al-Hussein K, Platanius LC, Gutierrez MI, Bhatia KG. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. **Oncogene. 2005;24:7022-30.**
258. Parmar S, Smith J, Sassano A, **Uddin S**, Katsoulidis E, Majchrzak B, Kambhampati S, Eklund EA, Tallman MS, Fish EN, Platanius LC. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. **Blood. 2005;106:2436-43.**
259. Kaur S, Parmar S, Smith J, Katsoulidis E, Li Y, Sassano A, Majchrzak B, **Uddin S**, Tallman MS, Fish EN, Platanius LC. Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. **Exp Hematol. 2005;33:550-7.**
260. **Uddin S**, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI, Bhatia KG. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. **Clin Cancer Res. 2005;11:3102-8.**
261. Lal L, Li Y, Smith J, Sassano A, **Uddin S**, Parmar S, Tallman MS, Minucci S, Hay N, Platanius LC. Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. **Blood. 2005;105:1669-77.**
262. **Uddin S**, Platanius LC. Mechanisms of type-I interferon signal transduction. **J Biochem Mol Biol. 2004;37:635-41.**
263. **Uddin S**, Hussain A, Al-Hussein K, Platanius LC, Bhatia KG. Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. **Biochem Biophys Res Commun. 2004 ;320:932-8.**
264. Lekmine F, Sassano A, **Uddin S**, Smith J, Majchrzak B, Brachmann SM, Hay N, Fish EN, Platanius LC. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. **Exp Cell Res. 2004;295:173-82.**

265. **Uddin S**, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A. Differentiation stage- specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. **Proc Natl Acad Sci U S A. 2004 ; 101:147-52.**
266. Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmar S, Giasis N, Kalvakolanu DV, Rahman A, **Uddin S**, Minucci S, Tallman MS, Fish EN, Platanius LC. Activation of protein kinase C delta by all-trans-retinoic acid. **J Biol Chem. 2003 ;278:32544-51.**
267. **Uddin S**, Lekmine F, Sassano A, Rui H, Fish EN, Platanius LC. Role of Stat5 in type I interferon-signaling and transcriptional regulation. **Biochem Biophys Res Commun. 2003;308:325-30.**
268. Lekmine F, **Uddin S**, Sassano A, Parmar S, Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN, Platanius LC. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. **J Biol Chem. 2003;278:27772-80.**
269. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, **Uddin S**, Rahman A, Fish EN, Platanius LC. Activation of protein kinase C delta by IFN- gamma. **J Immunol. 2003 ;171:267-73.**
270. G-Amlak M, **Uddin S**, Mahmud D, Damacela I, Lavelle D, Ahmed M, van Besien K, Wickrema A. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. **Biochem Biophys Res Commun. 2002 ;297:760-4.**
271. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, **Uddin S**, Mohindru M, Van Besien K, Platanius LC. Cutting edge: activation of the p38 mitogen- activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. **J Immunol. 2002 ;168:5984-8.**
272. **Uddin S**, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanius LC. Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. **J Biol Chem. 2002;277:14408-16.**
273. Verma A, Deb DK, Sassano A, **Uddin S**, Varga J, Wickrema A, Platanius LC. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. **J Biol Chem. 2002: 277:7726-35.**
274. Lekmine F, Sassano A, **Uddin S**, Majchrzak B, Miura O, Druker BJ, Fish EN, Imamoto A, Platanius LC. The CrkL adapter protein is required for type I interferon- dependent gene transcription and activation of the small G-protein Rap1. **Biochem Biophys Res Commun. 2002;291:744-50.**
275. Mahmud DL, G-Amlak M, Deb DK, Platanius LC, **Uddin S**, Wickrema A. Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. **Oncogene. 2002 ;21:1556-62.**
276. Masters J, Hinek AA, **Uddin S**, Platanius LC, Zeng W, McFadden G, Fish EN. Poxvirus infection rapidly activates tyrosine kinase signal transduction. **J Biol Chem. 2001;276:48371-5.**

277. Rahman A, Anwar KN, **Uddin S**, Xu N, Ye RD, Plataniias LC, Malik AB. Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. **Mol Cell Biol. 2001;21:5554-65.**
278. Mayer IA, Verma A, Grumbach IM, **Uddin S**, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Plataniias LC. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. **J Biol Chem. 2001;276:28570-7.**
279. Wong M, **Uddin S**, Majchrzak B, Huynh T, Proudfoot AE, Plataniias LC, Fish EN. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. **J Biol Chem. 2001 ;276:11427-31.**
280. Salti GI, Kichina JV, Das Gupta TK, **Uddin S**, Bratescu L, Pezzuto JM, Mehta RG, Constantinou AI. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. **Melanoma Res. 2001;11:99-104.**
281. Alsayed Y, **Uddin S**, Mahmud N, Lekmine F, Kalvakolanu DV, Minucci S, Bokoch G, Plataniias LC. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. **J Biol Chem. 2001 ;276:4012-9.**
282. Grumbach IM, Mayer IA, **Uddin S**, Lekmine F, Majchrzak B, Yamauchi H, Fujita S, Druker B, Fish EN, Plataniias LC. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. **Br J Haematol. 2001;112:327-36.**
283. **Uddin S**, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Plataniias LC. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. **J Biol Chem. 2000 ;275:27634-40.**
284. **Uddin S**, Kottegoda S, Stigger D, Plataniias LC, Wickrema A. Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. **Biochem Biophys Res Commun. 2000;275:16-9.**
285. Alsayed Y, Modi S, **Uddin S**, Mahmud N, Druker BJ, Fish EN, Hoffman R, Plataniias LC. All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells. **Exp Hematol. 2000;28:826-32.**
286. **Uddin S**, Majchrzak B, Wang PC, Modi S, Khan MK, Fish EN, Plataniias LC. Interferon-dependent activation of the serine kinase PI 3'-kinase requires engagement of the IRS pathway but not the Stat pathway. **Biochem Biophys Res Commun. 2000 ;270:158-62.**
287. Alsayed Y, **Uddin S**, Ahmad S, Majchrzak B, Druker BJ, Fish EN, Plataniias LC. IFN-gamma activates the C3G/Rap1 signaling pathway. **J Immunol. 2000;164: 1800-6.**
288. **Uddin S**, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, Young PR, Fish EN, Plataniias LC. Activation of the p38 mitogen-activated protein kinase by type I interferons. **J Biol Chem. 1999;274:30127-31.**
289. Wickrema A, **Uddin S**, Sharma A, Chen F, Alsayed Y, Ahmad S, Sawyer ST, Krystal G, Yi T, Nishada K, Hibi M, Hirano T, Plataniias LC. Engagement of Gab1 and Gab2 in erythropoietin signaling. **J Biol Chem. 1999;274:24469-74.**

290. Plataniias LC, **Uddin S**, Bruno E, Korkmaz M, Ahmad S, Alsayed Y, Van Den Berg D, Druker BJ, Wickrema A, Hoffman R. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. **Exp Hematol. 1999;27:1315-21.**
291. Chen YH, Lavelle D, DeSimone J, **Uddin S**, Plataniias LC, Hankewych M. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1). **Blood. 1999;94:251-9.**
292. Wickrema A, Chen F, Namin F, Yi T, Ahmad S, **Uddin S**, Chen YH, Feldman L, Stock W, Hoffman R, Plataniias LC. Defective expression of the SHP-1 phosphatase in polycythemia vera. **Exp Hematol. 1999;27:1124-32.**
293. Grumbach IM, Fish EN, **Uddin S**, Majchrzak B, Colamonici OR, Figulla HR, Heim A, Plataniias LC. Activation of the Jak-Stat pathway in cells that exhibit selective sensitivity to the antiviral effects of IFN-beta compared with IFN-alpha. **J Interferon Cytokine Res. 1999;19:797-801.**
294. Nadeau OW, Domanski P, Usacheva A, **Uddin S**, Plataniias LC, Pitha P, Raz R, Levy D, Majchrzak B, Fish E, Colamonici OR. The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation. Evidence that two Stat2 sites are required to reach a threshold of interferon alpha-induced Stat2 tyrosine phosphorylation that allows normal formation of interferon-stimulated gene factor 3. **J Biol Chem. 1999;274:4045-52.**
295. Fish EN, **Uddin S**, Korkmaz M, Majchrzak B, Druker BJ, Plataniias LC. Activation of a CrkL-stat5 signaling complex by type I interferons. **J Biol Chem. 1999;274:571-3.**
296. **Uddin S**, Alsayed Y, Grumbach I, Woodson J, Plataniias L. Cellular pathways activated by interferons in haematopoietic cells. **Haema. 1999; 2:180-1991.**
297. Azad N, LaPaglia N, Agrawal L, Steiner J, **Uddin S**, Williams DW, Lawrence AM, Emanuele NV. The role of gonadectomy and testosterone replacement on thymic luteinizing hormone-releasing hormone production. **J Endocrinol. 1998;158:229-35.**
298. **Uddin S**, Grumbach IM, Yi T, Colamonici OR, Plataniias LC. Interferon alpha activates the tyrosine kinase Lyn in haemopoietic cells. **Br J Haematol. 1998;101:446-9.**
299. Cichy SB, **Uddin S**, Danilkovich A, Guo S, Klippel A, Unterman TG. Protein kinase B/Akt mediates effects of insulin on hepatic insulin-like growth factor-binding protein-1 gene expression through a conserved insulin response sequence. **J Biol Chem. 1998;273:6482-7.**
300. Plataniias LC, Domanski P, Nadeau OW, Yi T, **Uddin S**, Fish E, Neel BG, Colamonici OR. Identification of a domain in the beta subunit of the type I interferon (IFN) receptor that exhibits a negative regulatory effect in the growth inhibitory action of type I IFNs. **J Biol Chem. 1998;273:5577-81.**
301. Choudhry MA, **Uddin S**, Sayeed MM. Prostaglandin E2 modulation of p59fyn tyrosine kinase in T lymphocytes during sepsis. **J Immunol. 1998 ;160:929-35.**
302. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, **Uddin S**, Plataniias LC, Rosen ST. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. **Blood. 1998 15;91:570-6.**

303. **Uddin S**, Fish EN, Sher D, Gardziola C, Colamonici OR, Kellum M, Pitha PM, White MF, Platanius LC. The IRS-pathway operates distinctively from the Stat- pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-alpha receptors. **Blood. 1997;90:2574-82.**
304. **Uddin S**, Sher DA, Alsayed Y, Pons S, Colamonici OR, Fish EN, White MF, Platanius LC. Interaction of p59fyn with interferon-activated Jak kinases. **Biochem Biophys Res Commun. 1997;235:83-8.**
305. Azad N, LaPaglia N, Kirsteins L, **Uddin S**, Steiner J, Williams DW, Lawrence AM, Emanuele NV. Jurkat cell proliferative activity is increased by luteinizing hormone- releasing hormone. **J Endocrinol. 1997;153:241-9.**
306. **Uddin S**, Fish EN, Sher DA, Gardziola C, White MF, Platanius LC. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-alpha. **J Immunol. 1997;158:2390-7.**
307. **Uddin S**, Sweet M, Colamonici OR, Krolewski JJ, Platanius LC. The vav proto- oncogene product (p95vav) interacts with the Tyk-2 protein tyrosine kinase. **FEBS Lett. 1997;403(1):31-4.**
308. **Uddin S**, Ahmad S. Role of some transition metal ion in oxygen-mediated toxicity. **Journal of scientific & industrial research. . 1997; 56:17-22.**
309. Platanius LC, **Uddin S**, Domanski P, Colamonici OR. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. **J Biol Chem. 1996 ;271:23630-3.**
310. **Uddin S**, Gardziola C, Dangat A, Yi T, Platanius LC. Interaction of the c-cbl proto-oncogene product with the Tyk-2 protein tyrosine kinase. **Biochem Biophys Res Commun. 1996;225(3):833-8.**
311. **Uddin S**, Wilson T, Emanuele MA, Williams D, Kelley MR, Emanuele N. Ethanol- induced alterations in the posttranslational processing, but not secretion of luteinizing hormone-releasing hormone in vitro. **Alcohol Clin Exp Res. 1996;20:556-60.**
312. **Uddin S**, Yetter A, Katzav S, Hofmann C, White MF, Platanius LC. Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product. **Exp Hematol. 1996;24:622-7.**
313. Platanius LC, **Uddin S**, Yetter A, Sun XJ, White MF. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. **J Biol Chem. 1996;271:278-82.**
314. **Uddin S**, Chamdin A, Platanius LC. Interaction of the transcriptional activator Stat-2 with the type I interferon receptor. **J Biol Chem. 1995;270 : 24627-30.**
315. Yetter A, **Uddin S**, Krolewski JJ, Jiao H, Yi T, Platanius LC. Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. **J Biol Chem. 1995;270:18179-82.**
316. **Uddin S**, Kirsteins L, LaPaglia N, Emanuele NV, Lawrence AM, Kelley MR, Emanuele MA. Failure of ethanol metabolites to alter gonadotropin secretion or luteinizing hormone synthesis in vitro. **Endocr Res. 1995;21:653-70.**

317. **Uddin S**, Yenush L, Sun XJ, Sweet ME, White MF, Platanius LC. Interferon- alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. **J Biol Chem. 1995;270:15938-41.**
318. **Uddin S**, Choudhry MA. Quercetin, a bioflavonoid, inhibits the DNA synthesis of human leukemia cells. **Biochem Mol Biol Int. 1995;36:545-50.**
319. **Uddin S**, Katzav S, White MF, Platanius LC. Insulin-dependent tyrosine phosphorylation of the vav protooncogene product in cells of hematopoietic origin. **J Biol Chem. 1995;270:7712-6.**
320. Musarrat J, Arezina J, **Uddin S**, Wani AA. Induction and processing of promutagenic O4-ethylthymine lesion in specific gene segments of plasmid DNA. **Biochim Biophys Acta. 1995 ;1260:276-84.**
321. **Uddin S**, Ahmad S. Antioxidants protection against cancer and other human diseases. **Compr Ther. 1995;21:41-5.**
322. **Uddin S**, Hadi SM. Reactions of furfural and methylfurfural with DNA. **Biochem Mol Biol Int. 1995;35:185-95.**
323. **Uddin S**, Ahmad S. Dietary antioxidants protection against oxidative stress. **Biochemical education. 1995 ; 23:2-7.**
324. Platanius LC, **Uddin S**, Colamonici OR. Tyrosine phosphorylation of the alpha and beta subunits of the type I interferon receptor. Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein. **J Biol Chem. 1994;269:17761-4.**
325. **Uddin S**, Emanuele MA, Emanuele NV, Reda D, Kelley MR. The effect of in vitro ethanol exposure on luteinizing hormone and follicle stimulating hormone mRNA levels, content, and secretion. **Endocr Res. 1994 ;20:201-17.**
326. **Uddin S**. Repair of quercetin-induced single-strand breaks by a cell free system. **Biochem Mol Biol Int. 1994;32:341-7.**
327. Emanuele MA, Halloran MM, Tentler JJ, **Uddin S**, Emanuele NV, Kelley MR. The effects of ethanol on pituitary function. **Compr Ther. 1994;20:326-30.**
328. Azad N, **Uddin S**, La Paglia N, Kirsteins L, Emanuele NV, Lawrence AM, Kelley MR. Luteinizing hormone-releasing hormone (LHRH) in rat prostate: characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats. **Endocrinology. 1993;133(3):1252-7.**
329. **Uddin S**. In vitro effects of methylfurfural on the secondary structure of DNA. *Medical Science Research*. 1993; 21(22):825-826.
330. **Uddin S**. Effect of furfural on the secondary structure of DNA. **Medical Science Research. 1993; 21:545-546.**
331. Emanuele MA, Halloran MM, **Uddin S**, Tentler J, Emanuele NV, Lawrence A, Kelley M. The effects of alcohol on the neuroendocrine control of reproduction. **National Institutes of Health Monograph 23. 1993; Chapter 5:89-116.**

332. **Shahabuddin**, Rahman A, Hadi SM. Reaction of furfural and methylfurfural with DNA: use of single-strand-specific nucleases. **Food Chem Toxicol. 1991;29:719-21.**
333. Rahman A, **Shahabuddin**, Hadi SM, Parish JH. Complexes involving quercetin, DNA and Cu(II). **Carcinogenesis. 1990;11 :2001-3.**
334. Rahman A, **Shahabuddin**, Hadi SM. Formation of strand breaks and interstrand cross-links in DNA by methylglyoxal. **J Biochem Toxicol. 1990 ;5:161-6.**
335. **Shahabuddin**, Rahman A, Hadi SM. Specificity of the in vitro interaction of methylfurfural with DNA. **Mutagenesis. 1990;5:131-6.**
336. Rahman A, **Shahabuddin**, Hadi SM, Parish JH, Ainley K. Strand scission in DNA induced by quercetin and Cu(II): role of Cu(I) and oxygen free radicals. **Carcinogenesis. 1989;10:1833-9.**
337. Hadi SM, **Shahabuddin**, Rehman A. Specificity of the interaction of furfural with DNA. **Mutat Res. 1989;225:101-6.**
338. Hadi SM, Rizvi RY, Rahman A, **Shahabuddin**. Dietary mutagens and Carcinogens. **JOURNAL OF SCIENTIFIC & INDUSTRIAL RESEARCH . 1987; 46:54-60.**
339. Rizvi RY, **Shahabuddin**, Rahman A, Hadi SM. Effect of alkylation with streptozotocin on the secondary structure of DNA. **Biosci Rep. 1986;6:557-64.**

### **Book Chapter**

340. Emanuele MA, Halloran MM, **Uddin S**, Tentler JJ, Lawrence AM, , Emanuel NV, Kelley MR. The reproductive neuroendocrinology of aging and drug abuse. Barnes C, Sarkar D, editors. London: Boca Raton, FL \* CRC Press; 1993. Chapter Chap. 13.
341. Prabhu KS, Kuttikrishnan S, Mohammad RM, **Uddin S**. Nucleic Acid – Structure and Functions; Quick Revision of Molecular Biology pp 245-270, **Research India Publications (ISBN: 978-93-84443-21-4) 2016; Book Chapter.**
342. Khan AQ, Siveen KS, Prabhu, Kuttikrishnan S, , Akhtar S, Shanmugakonar M, Al- Naemi HA, Haris M, Uddin S. Role of animal research in human malignancies. Animal Models in Cancer Drug discovery pp 1-29, Academic Press **Elsevier Publication(ISBN: 9780128147047) 2019.**
343. Khan AQ, Rashid K, Raza SS, Khan R, Mraiche F, **Uddin S**. Role of 3D tissue engineering models for human cancer and drug development. Animal Models in Cancer Drug discovery pp 309-320, Academic Press **Elsevier Publication(ISBN: 9780128147047) 2019.**
344. Raza A, Merhi M, Relecom A, Fernandez Q, Inchakalody VP, Gul AR, **Uddin S**, Al Homsy M, Dermime S. Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer book Cancer Targeted Immunotherapy in the Era of Precision Medicine, **ISBN 978-1-83968-868-3. DOI: 10.5772/intechopen.96494: 2021.**



345. Patil K Dermime S, and **Uddin S**. Extracellular Vesicle in hepatocellular Carcinoma: from initiation to metastasis. Book chapter, Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, **ISBN.DOI:(2021)-2022.**
346. Al-Ejeh F, Merhi M, Al-Muftah M, Fernandes Q, Al-Zaidan L, Bedhiafi T, Mestiri S, Moustafa D, Taib N, Inchakalody V, Raza A, **Uddin S**, Dermime S. Proteomic understanding of SARS-CoV-2 infection and COVID-19: biological, diagnostic, and therapeutic perspectives. **Omics approaches and technologies in COVID-19. ISBN.DOI:Accepted (2022).**
347. Mohi-ud-din M, Jan R, Khan R, Hashem S, Mir R, Elfaki I, Masoodi T, **Uddin S**, Macha MA, Bhat AA. (2023). Tight Junctions, Epithelial-Mesenchymal Transition, and Cancer Metastasis. In: Bhat, A.A., Haris, M., Macha, M.A., Dhawan, P. (eds) Tight Junctions in Inflammation and Cancer. Springer, Singapore. 10.1007/978-981-99-2415-3.
348. Fernandes Q. Ansari WA, Maalej KM, Merhi M, Dermime S, Ahmad A, **Uddin S**. Role of IL10 mediated signaling in pathogenesis of Multiple Myeloma. **International Review of Cell and Molecular Biology 396; 2025.**
349. Kuttikrishnan S. Prabhu KS, Mariyam Z , Habiba U, Ahmad N, Fernandes Q, Khan OM, Bhat AA, **Uddin S**. Soluble immune checkpoint molecules and regulatory cytokines as biomarkers of response in lung cancer therapy. **International Review of Cell and Molecular Biology. 396; 2025.**
350. Chauhan R, Gupta A, Dagar G, Sharma S, Sadida HQ, Hashem S, Verghese AM, Tanwar M, Macha MA, **Uddin S**, Ammira ASA, Pandita TK, Bhat AA, Singh M. Role of Lamins in Cellular Physiology and Cancer. **Adv Protein Chem Struct Biol (Accepted) 2024**

### **Abstracts/Presentation /Meetings**

1. Fernandes Q, Murshed K, Abo Samra H, Inchakalody VP, Merhi M, **Uddin S**, Petkar M, Babu GR, Moustafa AE, Dermime S. Synergistic Effects of High-Risk Human Papillomaviruses and Epstein-Barr Virus in Advanced Colorectal Cancer Patients in Qatar. Best of ASCO 2024. Le Royal Meridien Hotel, Doha (received 1<sup>st</sup> price)
2. Fernandes Q, Inchakalody VP, Merhi M , Yempally V, Bedhiafi T, Sahir F, Hydrose S; Mestiri S, Madrihamov S, **Uddin S**, Moustafa AE, Bengali AA, Dermime S. In-vitro & In-vivo Analysis of the Anti-oncogenic potential of Rhenium Carbonyl Complexes in Cancer. Best of ASCO 2022. Doha (received 3<sup>rd</sup> place)
3. Fernandes Q, Gupta I, Narayanan SP, Koshy JS, Murshed K, Samra HA, Inchakalody VP, Al-Thawadi H, Vranic S, Merhi M, Petkar M, **Uddin S**, Dermime S, Babu GB, Moustafa AE. Incidence Association and Implied Cooperation of High-risk Human Papillomaviruses and the Epstein-Barr virus in Patients with Advanced Stages of Colorectal Cancer from Qatar. 8th QU Health Symposium 2024, Qatar University, Doha. (Received 1<sup>st</sup> place)
4. Fernandes Q, Inchakalody VP, Merhi M, Yempally V, Bedhiafi T, Sahir F, Hydrose S, Mestiri S, Madrihamov S, **Uddin S**, Moustafa AE, Bengali AA; Dermime S. A Novel

Rhenium-based Chemotherapy Drug for Colorectal Cancer; An In-vitro and In-vivo Analysis. Qatar University Annual Research Forum 2023. Qatar University, Doha (Received 1<sup>st</sup> place)

5. Kuttikrishnan S, Masoodi, T, Ahmad F, Sher G, Prabhu KS, Mateo JM, Buddenkotte J, Elimat T, Oberlies N, Pearce CJ, Bhat AA, Alali, FQ, Steinhoff M, **Uddin S**. In Vitro Evaluation of Neosetophomone B Inducing Apoptosis in Cutaneous T Cell Lymphoma by Targeting the FOXM1 Signaling Pathway. Best of Asco-2023, Le Royal Méridien Doha
6. Prabhu KS, Ahmad F, Kuttikrishnan S, Leo R, Ali TA, Izadi M, Mateo JM, Alam M, Ahmad A, Akil ASA, Bhat AA, Buddenkotte J, Pourkarimi E, Martin Steinhoff M, **Uddin S**. Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and *C. elegans*. Best of Asco-2023, Le Royal Méridien Doha
7. Maram H, Kuttikrishnan S, Tamam E, Nicholas O, Pearce CJ, Alali FQ, **Uddin S**, Yalcin H. Assessment of anticancer activity of Neosetophomone B in vivo using Zebrafish xenograft model. Annual Research Form & Exhibition 2023, Qatar University.
8. Kuttikrishnan S, Prabhu KS, Khan AQ, Elimat T, Khalil A, Oberlies N, Alali FQ, **Uddin S**. Anticancer activity of Neosetophomone B, a fungal secondary metabolite, against leukemic cell lines. QUARFE'21, 2021. Qatar University, Doha, Qatar.
9. Kuttikrishnan S, Prabhu KS, Khan AQ, Elimat T, Khalil A, Oberlies N, Alali FQ, **Uddin S**. Anticancer activity of Neosetophomone B, an aquatic fungal secondary metabolite, against leukemic cell lines. 10th Annual Meeting of the Middle-Eastern Association for Cancer Research, 2020. Doha, Qatar.
10. Kuttikrishnan S, Prabhu KS, Khan AQ, Elimat T, Khalil A, Oberlies N, Alali FQ, **Uddin S**. Anticancer activity of Neosetophomone B, an aquatic fungal secondary metabolite, against leukemic cell lines. 10<sup>th</sup> CPH Forum, Qatar University. Doha, Qatar.
11. Prabhu KS, Khanjar B, Kuttikrishnan S, Khan AQ, Fathima H, Jochebeth A, Siveen KS, Buddenkotte J, **Uddin S**. Bortezomib mediated upregulation of p21/p27 expression through suppression of SKP2/AKT axis in Epidermoid Carcinoma cells. Hamad Annual Research Day, January 25, 2020.
12. Kuttikrishnan S, Prabhu KS, Khan AQ, Faiyaz A, Fathima H, Zafar M, Siveen KS, Dermime S, **Uddin S**. Targeting of FOXM1 by thioestrepton inhibits growth and induces apoptosis in B-precursor Acute Lymphoblastic Leukemia (B-pre ALL) cells. Hamad Annual Research Day, January 25, 2020.
13. Khan AQ, Nazeer A, Ishrat H, Fathima H, Tasni R, Agha MH, Anh J, Prabhu KS, Siveen KS, Kuttikrishnan S, Dermime S, Steinhoff M, **Uddin S**. Targeting JAK/STAT3 signaling pathway induces apoptosis in papillary thyroid cancer and cancer stem like cells. Hamad Annual Research Day, January 24, 25, 2019.
14. Prabhu KS, Khanjar B, Kuttikrishnan S, Khan AQ, Fathima H, Jochebeth A, Kodapully SS, Buddenkotte J, Steinhoff M, **Uddin S**. Bortezomib mediated upregulation of p21/p27 expression through suppression of Skp2/AKT axis in Epidermoid carcinoma cells. Hamad Annual Research Day, January 24, 25, 2019.

15. Kuttikrishnan S, Prabhu KS, Khan AQ, Faiyaz A, Fathima H, Zafar M, Kodappully SS, Dermime S, Steinhoff M, Alali FQ, **Uddin S**. Targeting of FoxM1 by thiostrepton inhibits growth and induces apoptosis in B-precursor Acute Lymphoblastic Leukemia (B-pre ALL) cells. Hamad Annual Research Day, January 24,25,2019.
16. Kuttikrishnan S, Prabhu KS, Siveen KS, Khan AQ, Akhtar S, Eiman AI, Zafar M, Merhi M, Mraiche F, Dermime S, **Uddin S**. Targeting of Pre B Acute Lymphoblastic Leukemia (Pre B-ALL) with curcumin induces Cytotoxic Effects via inactivation of Protein Kinase B and Activation of Mitochondrial Apoptotic pathways. Hamad Annual Research Day, December 5,2018.
17. Khan AQ, Eiman AI, Noor E, Akhtar S, Prabhu KS, Siveen KS, Kuttikrishnan S, Raza A, Mraiche F, Dermime S, **Uddin S**. Targetic of S-phase Kinase Association Protein 2(SKP2) in Human Papiloma Virus Positive and Negative Head and Neck Squamous Cell Carcinoma Cancer. Hamad Annual Research Day, December 5,2018.
18. Akhtar S , Achkar I, Kuttikrishnan S , Siveen KS, Prabhu KS, Khan AQ, Abdullah Hamzeh Shor, Merhi M, Ruba Taha, Halima El Omri, Dermime S, **Uddin S**. Targeting of Jak/Sat3 Signaling Pathway in Multiple Myeloma Cell Lines. Hamad Annual Research Day, December 5,2018.
19. Khan AQ, Achkar IW, Prabhu KS, Kuttikrishnan S, Siveen KS, Raza A, Mraiche F, Dermime S, **Uddin S**. Curcumin inhibits growth of human malignant HNSCC cells via down regulation of S-phase kinase associated protein2 (SKP2). Doha- Heidelberg research conference, Doha December 26-27, 2017
20. Achkar IW, Siveen K S, Prabhu KS, Kuttikrishnan S, KhanAQ, Kumar J, Merhi M, Raza A, Dermime S, Uddin S. Anticancer potential of sanguinarine in multiple myeloma cell lines. Doha-Heidelberg research conference, Doha December 26- 27, 2017
21. Gul ARZ, Raza A, Merhi M, Inchakalody VP, Allahverdi N, Uddin S, Knuth ARK, Dermime S. Anti-PD-1 (Nivolumab) as a first line treatment showed durable clinical response with differential expression of immunological biomarkers in metastatic type 2 papillary non-clear renal cell carcinoma (mPRCC). Doha- Heidelberg research conference, Doha December, 26-27, 2017
22. Merhi M, Al-Hijji MBI, Pittari G, Jalis M, Uddin S, Knuth ARK, Said Dermime . Blocking of PD-1 protein enhances functional activity of Viral specific T cells generated for the treatment of viral infections after allogeneic hematopoietic stem cell transplantation. Doha-Heidelberg research conference, Doha December 26-27, 2017
23. Al Homsy UM, Merhi M, Raza A, Inchakalody VP, Nashwan AJJ, Allahverdi N, Krishnankutty R, Pittari G, Uddin S, Gul ARZ, Knuth ARK, Dermime S. Differential expression of immunological markers after anti-PD-1 (Nivolumab) treatment in a patient with squamous cell carcinoma. Doha-Heidelberg research conference, Doha December 26-27, 2017.
24. Inchakalody VP, Taleb S, Merhi M, Krishnankutty R, Therachiyil L, Raza A, Uddin S, Knuth ARK, Dermime S. In vitro induction of NY-ESO-1 tumor antigen expression in lung cancer

- cells after treatment with 5-Aza-2'-Deoxycytidine and X-irradiation. Doha-Heidelberg research conference, Doha December 26-27, 2017.
25. Sivaraman KS, Bettahi I, Jayakumar J, Ramanjaneya M, Azizi F, Miles J, Kuttikrishnan S, Prabhu KS, Uddin S, Mohammad RM. Pristimerin increases mitochondrial reactive oxygen species by inhibition of manganese-dependent superoxide dismutase leading to apoptosis in human colorectal cancer cells. Hamad Annual Research Day, November 30, 2017, Doha, Qatar.
  26. Prabhu KS, Sivaraman KS, Kuttikrishnan S. Achkar I, Bettahi I, Inchakalody V, Dermime S, Uddin S. Prabhu KS, Sivaraman KS, Kuttikrishnan S. Achkar I, Bettahi I, Inchakalody V, Dermime S, Uddin S. Sanguinarine induces apoptosis in lung cancer cells via inhibition of anti-apoptotic family proteins. Hamad Annual Research Day, November 30, 2017, Doha, Qatar.
  27. Prabhu KS, Sivaraman KS, Kuttikrishnan S. Iskandarani A, Merhi M, Elimat T, Oberlies N, Alali FO, Dermime S, Uddin S. Greenspore C, a novel compound inhibits and causes apoptosis in leukemic cell lines. Hamad Annual Research Day, November 30, 2017, Doha, Qatar.
  28. Kuttikrishnan S. Prabhu KS, Sivaraman KS, Achkar IW, Merhi M, Dermime S, Uddin S. Sanguinarine suppresses growth and induces apoptosis in childhood acute lymphoblastic leukemia. Hamad Annual Research Day, November 30, 2017, Doha, Qatar.
  29. Uddin S, Iskandarani A. Siveen KS, Bhat AA, Mir F, Kuliniski M, Nasr Mohammad RM. Bortezomib mediated downregulation of F-box protein, S-phase kinase-associated protein 2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. Qatar Foundation Annual Research Conference 2016, March 22-23, Doha, Qatar.
  30. Parabhu KS, Siveen KS Iskandarani, Kuttikrishnan S, Tsakou M, Krishnankutty R, Bhat AA, Mohammad M, Uddin S. Embelin-mediated apoptosis in leukemic cells via generation of reactive oxygen species. Qatar Foundation Annual Research Conference 2016, March 22-23, Doha, Qatar.
  31. Sivaraman SK, Bhat AA, Ramanjaneya M, Bettahi I, Jayakumar J, Prabhu KS, Kuttikrishnan S, TherachiyilL, UddinS, Mohammad RM. Pristimerin inhibits growth and induces apoptosis in Human Colorectal Cancer Cells through the generation of reactive oxygen species. Qatar Foundation Annual Research Conference 2016, March 22-23, Doha, Qatar.
  32. Tsakou M, Prabhu KS, Sartaj F, AL-Thani, El-Gamal AR, Elsayeghd D, Kuttikrishnan, S, Mohammad, RM, Uddin S, Shuaib A, Zakaria ER. Molecular and peritoneal microvascular changes cause peritoneal membrane dysfunction by

uremia-related mechanisms. Qatar Foundation Annual Research Conference 2016, March 22-23, Doha, Qatar

33. Bu R, Prabhakaran,S, Beg S, Jehan Z, Siraj AK, Ahmed M, Hussain AR, AlsobhiSA, Al-Dayel F, Uddin, S, Al-Kuraya KS. ALK overexpression is associated with activation of PI3K/AKT signaling pathway in PTC. AACR Annual Meeting 2015, April 18-22, Philadelphia, Pennsylvania, USA.
34. Beg S, Prabhakaran S, Bu R, Al-Assiri M, Sairafi R, Al-Dayel F, Al-Sanea N, Siraj AK, Uddin S, Al-Kuraya KS.Molecular markers and pathway analysis of Middle Eastern colorectal carcinoma. AACR Annual Meeting 2015, April 18-22, Philadelphia, Pennsylvania, USA.
35. Ahmed M, Hussain A, Begum R, Thangavel S, Ajarim DS, Beg S, Uddin S, Al- Kuraya KS. Over-expression of FoxM1 in breast cancer can be therapeutically targeted using thiostrepton. AACR Annual Meeting 2015, April 18-22, Philadelphia, Pennsylvania, USA.
36. Hussain AR, Ahmed M, Bu R, Beg S, Alrashed AA, Melosantos R, Ajarim DS, Uddin S, Al-Kuraya KS. Xiap over-expression is a poor prognostic marker in breast cancer and can be targeted to induce efficient apoptosis. AACR Annual Meeting 2015, April 18-22, Philadelphia, Pennsylvania, USA.
37. Uddin S, Ahmed M, Hussain AR, Al-Kuraya K. Embelin – induces reactive oxygen species mediated apoptosis in PTC cells. AACR 104<sup>th</sup> Annual Meeting 2013, April 6-10, Wshington, USA.
38. Ahmed M, Hussain AR, Al-Dayel F, Uddin S, Al-Kuraya K. Targeting of mTOR mediated signaling pathways in papillary thyroid cancer cells. AACR 104<sup>th</sup> Annual meeting 2013, April 6-10, Wshington, USA.
39. Jehan Z, Prabhakaran S, Bu R, Al-Sanea N, Abduljabbar A, Ashari L, Al-Homoud S, Al-Dayel F, Uddin S, Bavi P, Al-Kuraya K. Clinicopathological significance of ALK alterations in colorectal carcinoma. AACR 104<sup>th</sup> Annual Meeting 2013, April 6-10, Wshington, USA.
40. Hussain AR, Uddin S, Ahmed M, Al-Kuraya K. Combined inhibition of MTOR and AKT activity induces potent apoptosis in epithelial ovarian cancer cells. AACR 104<sup>th</sup> Annual Meeting 2013, April 6-10, Wshington, USA.
41. Bu R, Siraj AK, Bavi P, Belgaumi A, Al-Haqawi W, Al-Dayel F, Uddin S, Alkuraya F, Al-Kuraya K. Constitutional mismatch repair deficiency syndrome is a rare cause of cancer even in a highly consanguineous population. AACR 104<sup>th</sup> Annual Meeting 2013, April 6-10, Wshington, USA.
42. Bu R, Ahmed M, Bavi P, Sultana M, Al-Haqawi W, Uddin S, Al-Kuraya K. Role of Card10 mediated NF-KB activation in colorectal carcinoma cells. AACR 103<sup>rd</sup> Annual Meeting 2012, March 31-April 4, 2012, Chicago IL, USA.
43. Ahmed M, Hussain AR, Bavi P, Bu R, Al-Janadi S, Uddin S, Al-Kuraya K. Expression of Hypoxia-inducible factor (HIF-1alpha) mediates Matrix Metalloproteinases (MMP) in colorectal carcinoma progression. AACR 103<sup>rd</sup> Annual Meeting 2012, March 31-April 4, 2012, Chicago IL, USA.

44. Siraj AK, Alrasheed M, Bavi P, Hussain AR, Al-Sanea N, Al-Dayel F, Uddin S, Al-Kuraya K. A20 gene promoter methylation confers resistance to colorectal carcinoma cell lines. AACR 103<sup>rd</sup> Annual Meeting 2012, March 31-April 4, 2012, Chicago IL, USA.
45. Jehan Z, Al-Obaisi K, Uddin S, Al-Kuraya K. Embelin induces autophagy in ovarian cancer cells. AACR 103<sup>rd</sup> Annual Meeting 2012, March 31-April 4, 2012, Chicago IL, USA.
46. Hussain AR, Ahmed S, Ahmed M, Khan OS, Uddin S, Al-Kuraya K. Thymoquinone-mediated suppression of NF $\kappa$ B activity causes inhibition of cell viability and induces apoptosis in activated B-cell sub-type of diffuse large B-cell lymphoma. AACR 103<sup>rd</sup> Annual Meeting 2012, March 31-April 4, 2012, Chicago IL, USA.
47. Uddin S, Bu R, Thangavel S, Hussain AR, Al-Kuraya K. Torin2 targets mTOR activity and induces apoptosis in DLBCL cells. AACR 103<sup>rd</sup> Annual Meeting 2012, March 31-April 4, 2012, Chicago IL, USA.
48. Al-Dayel F, Jehan Z, Bavi P, Uddin S, Al-Kuraya K. FoxM1 a potential biomarker and attractive target in Middle Eastern epithelial ovarian cancers. AACR International Conference on New Horizons in Cancer Research, December 13-16, 2011, New Delhi.
49. Bavi P, Bu R, Hussain AR, Jehan Z, Amin T, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Al-Kuraya K, Uddin S. XIAP gene is overexpression in papillary thyroid carcinoma and is an attractive biomarker of prognostic and therapeutic significance. AACR International Conference on New Horizons in Cancer Research, December 13-16, 2011, New Delhi.
50. Uddin S, Hussain AR, Ahmed M, Al-Sanea N, AbdulJabbar A, Ashari LH, Al-Homoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Aberrant Promoter Methylation of TMS1 gene in Patients with Colorectal Carcinoma in Saudi Arabia. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
51. Siraj AK, Khalak H, Al-Rasheed M, Sultana M, Bavi P, Al-Sanea N, Abduljabbar A, Al-Homoud S, Ashari L, Al-Dayel F, Uddin S, Al-Kuraya FS, Al-Kuraya KS. Colorectal Cancer Risk Is Not Associated with Increased Levels of Homozygosity in a Population from Saudi Arabia. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
52. Siraj AK, Al-Rasheed M, Hussain AR, Bavi P, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Uddin S, Al-Kuraya KS. Frequent Promoter Methylation of HIC1 Gene in Papillary Thyroid Carcinoma and Cell Lines. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
53. Jehan Z, Bavi P, Abubakr J, Ahmed M, Sultana M, Al-Dayel F, Ghourab S, Uddin S, Al-Kuraya KS. Clinicopathological Significance of Key Regulatory Genes Modulating the NF $\kappa$ - $\beta$  Pathway in Middle Eastern Epithelial Ovarian Carcinoma. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
54. Ahmed M, Jehan Z, Bavi P, Hussain AR, Olayan AS, Saravanan T, Al-Dayel F, Ghourab S, Uddin S, Al-Kuraya KS. Prevalence of FoxM1 expression in Middle Eastern epithelial ovarian carcinoma patients and its potential role as a therapeutic target. 102nd Annual

- Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
55. Bu R, Jehan Z, Ahmed M, Bavi P, Hussain AR, Olyan AS, Al Dayel F, Ghourab S, Uddin S, Al-Kuraya KS. Fatty acid synthase is overexpressed in Middle Eastern epithelial ovarian carcinoma (EOC) and its inhibition potentiates cisplatin-mediated apoptosis in EOC cells. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  56. Bavi P, Aubaker J, Prabhakaran SE, Sultna M, Al-Dayel F, Saravanan T, Qadri Z, Balde V, Naidu P, Al-Dossari H, Uddin S, Al-Kuraya KS. JC Virus T-Antigen (SV40) is an independent prognostic marker for poor disease free survival in Epithelial Ovarian Carcinoma and is associated with p53 mutation, over- expression of c-MET and IGF-1. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  57. Abubaker J, Bavi P, Uddin S, Jehan Z, Ahmed M, Al-Sanea NA, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Sultana M, Al-Haqawi W, Al-Rasheed M, Hassan N, Qadri Z, George T, Prabhakaran SE, Balde V, Siraj AK, Al-Kuraya KS. Frequent inactivation of A20 and its prognostic significance in Middle Eastern Colorectal Carcinoma. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  58. Bavi P, Uddin S, Bu R, Ahmed M, Abubaker J, Dayel F, Balde V, Naidu P, Al-Dossari H, Qadri Z, Prabhakaran SE, Hussain AR, Al-Kuraya KS. Prognostic significance of NF- $\kappa$ B in Middle Eastern Diffuse Large B cell Lymphoma and efficacy of NF- $\kappa$ B inhibition as a viable therapeutic target. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  59. Bu R, Bavi P, Hussain AR, Jehan Z, Abubaker J, Al-Sanea NA, Abduljabbar AS, Ashari LH, Al-Homoud S, Al-Dayel F, George T, Qadri Z, Hassan N, Prabhakaran S, Ahmed M, Uddin S, Al-Kuraya KS. Clinico-pathological correlation of UBE2C alterations in colorectal carcinoma and efficacy of UBE2C inhibition by proteasome inhibitor as a viable therapeutic target. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  60. Abubaker J, Bavi P, Jehan Z, Al-Haqawi W, Sultana M, Belgaumi SM, Siraj S, Ajarim D, Al-Dayel F, Uddin S, Al-Kuraya KS. Role of NF- $\kappa$ B regulators-A20 and CARD11 in Middle Eastern Diffuse Large B cell lymphoma. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  61. Abubaker J, Bavi P, Jehan Z, Ahmed M, Al-Haqawi W, Sultana M, Prabhakaran S, Al-Sanea NA, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Clinicopathological Significance of CARD10 Alterations in Middle Eastern Colorectal Cancer. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  62. Jehan Z, Ahmed M, Bavi P, Hussain AR, Al-Sanea N, Abduljabbar A, Ashari L, Al-Homoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Co-expression of Cyclooxygenase-2 and FoxM1

- play a critical role in the pathogenesis of Colo- Rectal Carcinoma. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
63. Ahmed M, Bavi P, Hussain AR, Jehan Z, Olyan AS, Bu T, Al-Nuaim A, Al-Sobhi S, Amin T, Uddin S, Al-Kuraya KS. FoxM1 is an attractive therapeutic target in a subset of Papillary Thyroid Cancers. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  64. Bavi P, Bu R, Hussain AR, Ahmed M, Thangavel S, Al-Sobhi, Al-Nuaim A, Amin T, Ahmed M, Uddin S, Al-Kuraya KS. c-Met inhibition synergistically enhances death receptor-induced apoptosis via up-regulation of DR5 in Papillary Thyroid Cancer. 102nd Annual Meeting of American Association of Cancer Research, April 2- 6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  65. Bu R, Hussain AR, Ahmed M, Al-Obaisi KA, Uddin S, Al-Kuraya KS. Bortezomib-mediated Inhibition of NF-  $\kappa$ B Activity Leads to Induction of Apoptosis in Activated B-Cell like Diffuse Large B-Cell Lymphoma. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA
  66. Hussain A, Bu R, Bavi P, Ahmed M, Al-Obaisi KAS, Al-Sobhi S, Al-Nuaim A, Ahmed M, Amin T, Uddin S, Al-Kuraya KS. Bortezomib (Velcade) Induces p27Kip1 Expression through S-Phase Kinase Protein 2 Degradation in Papillary Thyroid Cancer. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  67. Belgaumi AF, Bu R, Hussain AR, Al-Obaisi KAS, Al-Mahr M, Uddin S, Al-Kuraya KS. Real-time RT-PCR of Terminal Deoxynucleotidyl Transferase (TdT) is a useful tool for identification of Minimal Leukemia in Cerebrospinal Fluid. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  68. Hussain AZ, Bavi P, Bu R, Ahmed M, Al-Nuaim A, Ahmed M, Al-Sobhi S, Amin T, Uddin S, Al-Kuraya KS. XIAP expression is associated with poor prognosis and is a promising therapeutic target for the treatment of Papillary Thyroid Carcinoma. 102nd Annual Meeting of American Association of Cancer Research, April 2- 6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  69. Hussain AR, Ahmed M, Ahmed SO, Bu R, Khan OS, Plataniias L, Al-Kuraya KS, Uddin S. Targeting NF- $\kappa$ B pathway with Bay11-7085 lead to inhibition of cell viability and apoptosis in primary effusion lymphoma cells. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  70. Ahmed M, Hussain AR, Ahmed SO, Bu R, Thangavel S, Plataniias LC, Al-Kuraya KS, Uddin S. Role of FoxM1 survival pathway in Primary Effusion Lymphoma cells. 102nd Annual Meeting of American Association of Cancer Research, April 2- 6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  71. Jehan Z, Hussain AR, Ahmed M, Ahmed SO, Al-Dayel F, Bavi P, Uddin S, Al-Kuraya KS. Resveratrol suppresses constitutive activation of AKT via generation of reactive oxygen species and induces apoptosis in diffuse large B cell lymphoma cell lines. 102nd Annual



- Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
72. Siraj, AK, Hussain AR, Ahmed M, Ahmed SO, Bu R, Al-Dayel F, Bavi P, Uddin S, Al-Kuraya KS. FoxM1 expression and its association with Matrix Metalloproteinases in diffuse large B-cell lymphoma. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  73. Uddin S, Siraj AK, Al-Rasheed M, Husain M, Bavi P, Al-Sanea N, Abduljabbar A, Al Homoud S, Ashari L, Al Dayel F, Al-Kuraya KS. Co-expression of c-Met and DR5 is an Independent Prognostic Marker for Better Survival in Colorectal Carcinoma. 102nd Annual Meeting of American Association of Cancer Research, April 2-6, 2011, Orange County Convention Center, Orlando, Florida, USA.
  74. Al-Kuraya K, Bavi P, Uddin S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. 2<sup>nd</sup> International Conference on Drug Discovery and Therapy, February 1-4, 2010, Dubai, UAE.
  75. Bu R, Hussain A, Ahmed M, Bavi P, Uddin S, Al-Kuraya KS. Inhibition of c-Met kinase induces in papillary thyroid cancer cells. Advances in Cancer Research: From the Laboratory to the Clinic, March 07-10, 2010, Dead Sea, Jordan.
  76. Hussain A, Uddin S, Ahmed M, Bu R, Ahmed S, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya K. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signaling. Advances in Cancer Research: From the Laboratory to the Clinic, March 07-10, 2010, Dead Sea, Jordan.
  77. Ahmed M, Bavi P, Hussain A, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya K. Aberrant COX-2 expression in Middle Eastern colorectal carcinoma. Advances in Cancer Research: From the Laboratory to the Clinic, March 07-10, 2010, Dead Sea, Jordan.
  78. Bavi P, Ahmed M, Hussain A, Jehan Z, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Balde V, Uddin S, Al-Kuraya K. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Advances in Cancer Research: From the Laboratory to the Clinic, March 07-10, 2010, Dead Sea, Jordan.
  79. Al-Kuraya K, Bavi P, Uddin S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. 5<sup>th</sup> International APOCP Conference, April 3-7, 2010, Istanbul, Turkey.
  80. Siraj AK, Al-Rasheed M, Hussain A, Bavi P, Al-Nuaim A, Al-Dayel F, Uddin S, Al-Kuraya K. TMSI Gene Promoter Methylation confers resistance to papillary thyroid carcinoma cell lines. Advances in Cancer Research: From the Laboratory to the Clinic, March 07-10, 2010, Dead Sea, Jordan.
  81. Uddin S, Hussain A, Ahmed M, Al-Dayel F, Bavi P, Al-Kuraya K. Inhibition of c-MET is a potential therapeutic strategy for treatment of Diffuse Large B-Cell Lymphoma. Advances in Cancer Research: From the Laboratory to the Clinic, March 07-10, 2010, Dead Sea, Jordan.

82. Uddin S, Hussain A, Bavi P, Al-Kuraya K. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in Diffuse Large B Cell Lymphoma. 51<sup>st</sup> ASH Annual Meeting and Exposition, December 05-08, 2009, New Orleans, L.A., USA.
83. Al-Kuraya K, Bavi P, Uddin S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. GTC 2<sup>nd</sup> Annual Biomarker Discovery Europe, October 12, 2009, Lisbon, Portugal.
84. Al-Kuraya K, Bavi P, Siraj AK, Uddin S. Enhanced leptin receptor expression identifies an aggressive subset of Middle Eastern papillary thyroid cancer. First AACR International Conference on Frontiers in Basic Cancer Research, October 8-11, 2009, Boston, Massachusetts, USA.
85. Bavi P, Siraj AK, Abubaker J, Devarajan S, Balde V, Atizado V, Al-Nuaim A, Ahmed M, Amin T, Alzahrani A, Al-Dayel F, Uddin S, Al-Kuraya K. Metallothionein expression is a marker of favorable prognosis in classical papillary thyroid carcinoma. World Congress on Thyroid Cancer, August 6-10, 2009, Toronto, Canada.
86. Al-Kuraya K, Uddin S, Bavi P, Al-Dayel F, Al-Sanea N. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. 5<sup>th</sup> Leukocyte Signal Transduction Conference, June 13-19, 2009, Crete, Greece.
87. Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Al-Harbi S, Munkarah A, Uddin S, Al-Kuraya KS. PIK3CA alterations in Middle Eastern ovarian cancers and its clinicopathological significance. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
88. Abubaker J, Bavi P, Al-Haqawi W, Moorji A, Al-Sanea, Abduljabbar A, Ashari LH, Alhomoud A, Al-Dayel F, Uddin S, Al-Kuraya KS. KRAS alteration in the Middle Eastern CRC and its clinicopathological significance. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
89. Hussain AR, Ahmed SO, Ahmed M, Plataniias LC, Al-Kuraya KS, Uddin S. Thymoquinone cause cell growth inhibition and induces apoptosis in primary effusion lymphoma cells via release of ROS. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
90. Hussain AR, Bavi P, Ahmed M, Al-Dayel F, Uddin S, Al-Kuraya KS. Clinicopathological significance of Hypoxia-inducible factor-1 $\alpha$  in Middle Eastern colorectal cancer. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
91. Siraj AK, Al-Rasheed M, Hussain AR, Bavi P, Siddiqui K, Ibrahim M, Al-Nuaim A, Al-Dayel F, Uddin S, Al-Kuraya KS. Methylation status of target of methylation associated silencing (TMS1) gene predicts outcome in Middle Eastern papillary thyroid cancer patient. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
92. Bavi P, Siraj AK, Al-Rasheed M, Devarajan D, Atizado V, Balde V, Ahmed M, Amin T, Ahmed M, Bu R, Uddin S, Al-Kuraya KS. Enhanced leptin receptor expression identifies an

- aggressive subset of middle eastern papillary thyroid cancer. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
93. Ahmed M, Bavi P, Hussain A, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Prevalence of COX2 expression in Middle Eastern CRC and the effect of COX2 inhibitors on cell growth in the mouse model of CRC. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
  94. Ahmed M, Jehan Z, Hussain AR, Munkarah A, Al-Dayel F, Bavi P, Uddin S, Al-Kuraya. Bortezomib induces apoptosis via SKP2 down regulation and synergizes with cisplatin in the killing of ovarian cancer cells. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
  95. Uddin S, Hussain AR, Ahmed S, Ahmed M, Bu R, Al-Dayel F, Bavi P, Al-Kuraya KS. Inhibition of fatty acid synthase suppresses c-met kinase overexpression in diffuse large B-cell lymphoma. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
  96. Uddin S, Hussain AR, Ahmed SO, Ahmed M, Al-Sanea N, AbdulJabbar A, Ashari L, Al-Homoud S, Bavi P, Al-Kuraya KS. c-Met inhibitor potentiates TRAIL-induced apoptosis in human Colo-rectal cancer cells. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
  97. Hussain AR, Ahmed SO, Ahmed M, Jehan Z, Al-Dayel F, Bavi P, Uddin S, Al-Kuraya KS. X-linked inhibitor of apoptosis protein expression is a bad prognostic marker in DLBCL and is regulated by hepatocyte growth factor/c-Met pathway via AKT pathway. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
  98. Jehan Z, Bavi P, Ahmed M, Hussain AR, George T, Moorji AZ, Al-Dossari H, Uddin S, Al-Kuraya KS. Prognostic value of ubiquitin-conjugating enzyme E2C expression in middle eastern CRC. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
  99. Bu R, Ahmed M, Sultana M, Munkarah A, Bavi P, Al-Dayel F, Uddin S, Al-Kuraya K. COX2 inhibition inhibits c-Met kinase activity and MMP expression in ovarian cancer. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
  100. Bu R, Hussain A, Ahmed SO, Uddin S, Al-Kuraya KS. Inhibition of c-Met as Therapeutic Strategy for Papillary Thyroid Cancer. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
  101. Bu R, Bavi P, Ahmed M, Hussain A, Munkarah A, Al-Dayel F, Uddin S, Al-Kuraya K. Overexpression of Leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.

102. Al-Thari S, Khan AS, Hussain AR, Ahmed M, Al-Kuraya KS, Uddin S. Curcumin- mediated suppression of AKT activity induces apoptosis in papillary thyroid carcinoma cell. AACR Annual Meeting, April 18-22, 2009, Colorado Convention Center, Denver, Colorado, USA.
103. Siraj AK, Bavi P, Sultana M, Abubaker J, Moorji A, Al-Sanea N, Al-Dayel F, Uddin S, Al-Kuraya K. Genome wide expression analysis of Middle Eastern CRC reveals FOX-M1 as a novel target for cancer therapy. AACR Annual Meeting, April 18- 22, 2009, Colorado Convention Center, Denver, Colorado, USA
104. Bavi P, Devarajan S, Atizado V, Balde V, Siddiqui S, Moorji A, Al-Dossary H, Ezzat A, Al-Dayel F, Uddin S, Al-Kuraya K. Reduced or absent cyclin dependant kinase (CAK) expression is an independent prognostic marker for poor outcome in diffuse large B cell lymphoma. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
105. Bavi P, Siraj AK, Al-Rasheed M, Devarajan S, Atizado V, Ahmed M, Amin T, AlNuaim A, Uddin S, Al-Kuraya K. Leptin and Leptin-R expression in papillary thyroid carcinoma. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
106. Bavi P, Ahmed M, Devarajan S, Moorji A, Atizado V, Balde V, Abduljabbar A, Alhomoud S, Ashari L, AlSanea N, Uddin S, Al-Kuraya K. Leptin-R is an independent prognostic marker in colorectal carcinoma. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
107. Uddin S, Ahmed M, Bavi P, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Hussain A, Al-Kuraya K. Bortezomib (Velcade) induces p27kip1 associated cell cycle arrest and apoptosis through down-regulation of SKP2 ubiquitin ligase pathway in colorectal carcinoma. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
108. Uddin S, Hussain A, Ahmed M, Khan A, Bavi P, Al-Kuraya K. Proteasome inhibitor MG-132 induces p27Kip1 expression through SKP2 degradation in diffuse large B cell lymphoma. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
109. Abubaker J, Jehan Z, Bavi P, Sultana M, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya K. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in Middle Eastern population. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
110. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Al-Hagawi W, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya K. PI3K/AKT and MAPK pathways cross talk and their possible role in CRC tumorigenesis of Middle Eastern population. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
111. Siraj AK, Al-Rasheed M, Ibrahim M, Al-Dayel F, Uddin S, Al-Kuraya K. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in

- Middle Eastern population. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
112. Siraj AK, Al-Rasheed M, Ahmed M, Ibrahim M, AlNuaim A, Al-Dayel F, Bavi P, Hussain A, Uddin S, Al-Kuraya K. Fatty acid synthase is a potential target for a subset of papillary thyroid cancers. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
  113. Ahmed M, Hussain A, Bavi P, Ibrahim M, El-Sayed R, Munkarah A, Uddin S, Al-Kuraya K. Proteasome inhibitor Bortezomib (Velcade®) induces apoptosis via degradation of SKP2 in ovarian cancer. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
  114. Ahmed M, Hussain A, Bavi P, Ibrahim M, El-Sayed R, Munkarah A, Uddin S, Al-Kuraya K. Apoptosis induced by aspirin via inhibition of AKT activity and downregulation of cyclooxygenase 2 expression. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
  115. Khan A, Hussain A, Ahmed M, Plataniias L, Uddin S, Al-Kuraya K. Apigenin down-regulates constitutive activation of AKT and induces apoptosis in primary effusion lymphoma cells. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
  116. Hussain A, Ahmed M, Al-Jomah N, Khan A, Ahmed S, Sultana M, Manogaran P, Abubaker J, Plataniias L, Al-Kuraya K, Uddin S. Curcumin requires constitutive activation of NFκB and functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
  117. Hussain A, Ahmed M, Bavi P, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya K. Fatty acid synthase inhibition suppresses p-AKT and induces apoptosis in colorectal carcinoma. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
  118. Jehan Z, Abubaker J, Bavi P, Uddin S, Al-Kuraya K. Genetic alterations of PIK3CA in Liver cancer of Saudi Arabia. AACR Annual Meeting, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
  119. Jehan Z, Bavi P, Hussain A, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya K. PIK3CA amplification is an independent predictor of better survival in colon cancer patients of Middle East. AACR Annual Meeting 2008, April 12-16, 2008, San Diego Convention Center, San Diego, California, USA.
  120. Al-Kuraya K, Uddin S, Abduljabbar A, Ashari L, Alhomoud S, Al-Sanea N. Targetting of ubiquitin-proteasome pathway is a potential therapy for colorectal carcinoma. Genes and Cancer 2007, December 10-12, 2007, University of Warwick, UK.
  121. Uddin S, Hussain A, Khan AS, Bavi P, Alkuraya KS. Inhibition of Ubiquitin-proteasome pathway causes growth suppression and induces apoptosis in diffuse large B cell lymphoma. 49th American Society of Hematology, held in Atlanta Georgia, USA, Dec, 2007.

122. Munkara A, Uddin S, Hussain A, Al-Jomah N, AL-Herbi S, Al-Kuraya. Aspirin induces apoptosis in ovarian cancer cells via inhibition of AKT activity and downregulation of cox-2 expression. AACR-Cancer Research conference Amman Jordan, September 3-4, 2007.
123. Uddin S, Ahmed M, Bavi P, Al-Jomah N, Khan AS, El-Sayed R, Al-Sanea N, Abdul Jabbar A, Luai Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya K. PS-341 (Velcade) Induces p27 Expression through SKP Degradation in Colorectal Cancer. AACR-Cancer Research conference Amman Jordan, September 3-4, 2007.
124. Al-Sanea N, Jabbar AA, Ashari LH, Alhomoud S, Al-Jomah N, Ahmed M, Hussain AR, Uddin S, AL-Kuraya KS. Proteasome inhibitor PS-341 (Velcade) causes cell growth arrest and apoptosis in colorectal carcinomas. 9th World Congress on Gastrointestinal Cancer, June 27-30, Barcelona, Spain.
125. Al-Sanea N, Jabbar AA, Ashari LH, Alhomoud S, Uddin S, Bavi, PP, AL-Kuraya KS. Significance of p27Kip1 expression and Ubiquitin Ligase subunit SKP-2 in Saudi colorectal carcinoma. 9th World Congress on Gastrointestinal Cancer, June 27-30, Barcelona, Spain.
126. Al-Sanea N, Jabbar AA, Ashari LH, Alhomoud S, AL-Herbi S, Abubaker J, Bavi, P, Uddin S, AL-Kuraya KS. Correlation Of PIK3 Mutations with Microsatellite Instability In Colorectal Carcinomas From The Middle East. 9th World Congress on Gastrointestinal Cancer, June 27-30, Barcelona, Spain.
127. Bavi P, Atizado V, Balde V, Al-Dayel F, Ezzat A, Uddin S, Al-Kuraya K. Lack of cyclin H expression is independent prognostic marker for poor outcome in diffuse large B cell lymphoma. American Society of Cancer Research, April 14-18, 2007, Los, Angeles, USA.
128. Uddin S, Hussain AR, Al-Jomah N, Sultana M, Ahmed M, Al-Kuraya K, Proteasome inhibitor induces apoptosis in primary effusion lymphoma. American Society of Cancer Research, April 14-18, 2007, Los, Angeles, USA.
129. Hussain AR, Siraj AK, Sultana M, Al-Rasheed M, Jehan Z, Belgaumi A, El-Solh H, Uddin S, Al-Kuraya K. Molecular signatures in childhood acute lymphoblastic leukemia in the Kingdom of Saudi Arabia. American Society of Cancer Research, April 14-18, 2007, Los, Angeles, USA.
130. Hussain AR, Al-Jomah N, Siraj AK, Abubaker J, Al-Kuraya K, Uddin S. Sanguinarine induces apoptosis via up-regulation of death receptor 5 in primary effusion lymphoma. American Society of Cancer Research, April 14-18, 2007, Los, Angeles, USA.
131. Abubaker J, Bavi P, Al-Harbi S, Mourad W, Al-Dayel F, El-Solh H, Ezzat A, Uddin S, Al-Kuraya K. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B cell lymphoma. American Society of Cancer Research, April 14-18, 2007, Los, Angeles, USA.
132. Hussain AR, Al-Jomah N, Sultana M, Pulicat M, Al-Kuraya K, Uddin S. Proteasome Inhibitor Treatment Down-Regulates S-Phase Kinase-Associated Protein 2 Causing Inhibition of Proliferation and Induces Apoptosis in Primary Effusion Lymphoma. American Society of Hematology, Orlando, Florida, USA, Dec 9-12, 2006.
133. Hussain AR, Al-Jomah N, Siraj AK, Pulicat M, Al-Hussein K, Al-Kuraya K, Uddin S. Up-Regulation of Death Receptor 5 and Bax Translocation Is Necessary To Induce Apoptosis

- by Sanguinarine in Primary Effusion Lymphoma. American Society of Hematology, Orlando , Florida, USA, Dec 9-12, 2006.
134. Siraj AK, Bu R, Al-Rasheed M, Ibrahim M, Ezzat A, El-Solh H, Uddin S, Al-Kuraya K. Genetic Polymorphisms of Methylenetetrahydrofolate Reductase Genes and Diffuse Large B-Cell Lymphoma Risk in Middle Eastern Population. American Society of Hematology, Orlando , Florida, USA, Dec 9-12, 2006.
  135. Uddin S, Hussain A, Bavi P, Al-Kuraya K. Significance of Ubiquitin Ligase Subunit SKP-2 Proto-Oncogene and Proliferative Marker Ki67 Expression in Diffuse Large B-Cell Lymphoma. American Society of Hematology, Orlando , Florida, USA, Dec 9-12, 2006.
  136. Abubaker JA, Bavi P, Al-Harbi S, Atizado V, Al-Dayel F, Ezzat A, Uddin S, Al-Kuraya K. Frequent Mutation of the PIK3CA Gene in Saudi Arabian Diffuse Large B-Cell lymphoma. American Society of Hematology, Orlando , Florida, USA, Dec 9-12, 2006.
  137. Siraj AK, Bu R, Al-Rasheed M, Ibrahim M, Bavi P, Abubaker J, Al-Jomah N, Mourad W, Al-Dayel F, Ezzat A, El-Solh H, Uddin S, Al-Kuraya K. Association between Drug-Metabolizing Enzymes Polymorphisms and Diffuse Large B-Cell Lymphoma Risk in the Middle Eastern Population. American Society of Hematology, Orlando , Florida, USA, Dec 9-12, 2006.
  138. Munkarah AR, Uddin S, Hussain A, Al-Harbi S, Al-Jomah N, Saed G, Al-Kuraya K. Aspirin induces apoptosis in Ovarian Cancer Cells via inhibition of AKT activity and down-regulation of COX-2 expression. International Gynecologic Cancer Society, October 14-18, Santa Monica, California, USA.
  139. Siraj AK, Jehan Z, Abubaker J, Ruiz C, Simon R, Sultana M, Uddin S, Bavi P, Ezzat A, El-Solh H, Al-Dayel F, Sauter G, Al-Kuraya K. Distinct Gene Expression Profiles Characterize the Nodal vs Extra-Nodal Diffuse Large B-Cell Lymphoma in KSA. International Symposium Cancer, November 7-9, 2006, Riyadh, Saudi Arabia.
  140. Al-Nuaim A, Al-Zahrani A, Ahmed M, Al-Arifi A, Al-Mahfouz A, Raef A, Abubaker A, Uddin S, Jehan J, Siraj AK, Bavi P, Al-Kuraya KS. Gene Expression Profiling Identifies Insulin Growth Factor Related Genes (IGF2R, IGFBP3) and Mucin 1 Transmembrane (MUC1) as Prognostic Markers for Papillary Thyroid Carcinoma in Saudi Arabia. Endo 2006, June 24-27, Boston, USA
  141. Uddin S., Hussain A, Bavi P, Siraj AK, Al-Kuraya K. Inhibition of Phosphatidylinositol 3-Kinase/AKT Pathway in Diffuse large B-cell lymphoma Survival. American Society of Cancer Research, Washington DC, USA, April 1- 5, 2006.
  142. **Uddin S.**, Hussain A., Bavi P, Siraj AK, Al-Kuraya K. Role of Phosphatidylinositol 3-Kinase/AKT Pathway in Diffuse large B-cell lymphoma Survival. American Society of Hematology, Atlanta, Georgia, USA, Dec 10-13, 2005.
  143. **Uddin S.** Al-Kuraya K. Apigenin induces apoptosis in primary effusion lymphoma. 47<sup>th</sup> American Society of Hematology, Atlanta, Georgia, USA, Dec 10-13, 2005.

144. Hussain A, Siraj AK, Manogaran PS, Al-Hussein KA, Al-Kuraya K, **Uddin S**. Curcumin Induces Apoptosis by Inhibiting the Expression of IAPs in Human Precursor B-Acute Lymphoblastic Leukemia (PreB-ALL) Cells. 47<sup>th</sup> American Society of Hematology, Atlanta, Georgia, USA, Dec 10-13, 2005.
145. Hussain A, Al-Rasheed, Manogaran PS, Al-Kuraya K, **Uddin S**. Complete Loss or Severely Compromised Expression of the Pro-Apoptotic Protein Bax Leads to Resistance to Curcumin-Induced Apoptosis in Burkitt's Lymphoma. 47<sup>th</sup> American Society of Hematology, Atlanta, Georgia, USA, Dec 10-13, 2005.
146. **Uddin S**, Curcumin induced apoptosis in Lymphoma, Free radical in Health and nutrition, Bangalore, India (Invited speaker) Jan 10-13, 2005.
147. Wickrema A, **Uddin S**, Ulaszek J and Ah-Kang J. Activation of p70S6 kinase in primary human erythroid cells. 46<sup>th</sup> American Society of Hematology, San Diego, USA, Dec 4-7, 2004.
148. **Uddin S**, Hussain A, Gutierrez MI, Bhatia K. Coaxing primary effusion lymphomas into committing suicide; A potential therapeutic strategy. INCTR, October 1-5, Egypt, 2004.
149. Hussain A, **Uddin S**, Al-Hussein K, Manogaran PS, Gutierrez, MI, Bhatia K. Role of PI3-kinase pathway in primary effusion lymphoma survival. 46<sup>th</sup> American Society of Hematology, San Diego, USA, Dec 4-7, 2004
150. **Uddin S**, Hussain, Al-Hussein, Gutierrez M, Bhatia K. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma cells. 46<sup>th</sup> American Society of Hematology, San Diego, USA, Dec 4-7, 2004.
151. **Uddin S**, Ulaszek J, Ah-Kang J, Van Besien K, Zimmerman T, Wickrema A. Small Molecule Inhibitors of Glycogen Synthase Kinase-3 Suppress Myeloma Cell Growth by Activation of Forkhead Transcription Factors. Blood (suppl.1) 2003.
152. Verma A, Deb DK, Sassano A, **Uddin S**, Kambhampati S, Varga J, Wickrema A, Mohindru M, Van Besien K and Plataniias LC. Regulatory effects of activation of the p38 Map kinase signaling cascade on human hematopoiesis in response to interferon and other cytokines. Interf. Cyt. Conf.2001.
153. Mayer IA, Grumbach IM, Fujita S, **Uddin S** and Plataniias LC. Activation of the p38 Map kinase pathway mediates the growth inhibitory effects of IFN- $\alpha$  in chronic myelogenous leukemia. Blood 96 (Suppl. 1):347, 2000.
154. Alsayed Y, **Uddin S**, Modi S and Plataniias LC. All- trans-retinoic acid induces tyrosine phosphorylation of CBL and CrkL in NB-4 acute promyelocytic leukemia cells. Blood. 94 (Suppl. 1): 180, 1999.
155. **Uddin S**, Alsayed Y and Plataniias LC. Activation of the p38 Map kinase by all- trans-retinoic acid in acute promyelocytic leukemia cells. Blood 94 (Suppl. 1):160, 1999.



156. Alsayed Y, **Uddin S**, Ahmad S, Majchrzak B, Druker BJ, Bos J, Fish EN and Platanius LC. Interferon- $\alpha$  and interferon- $\gamma$  induce activation of the small G-protein Rap1. *Blood* 94 (Suppl. 1): 472, 1999.
157. Platanius LC, Fish EN, Woodson J, Alsayed Y, Arunkumar P, Pine R, Young P, Majchrzak B and **Uddin S**. The p38 Map kinase is activated by Type I interferons and is required for Type I IFN-dependent gene transcription. *J. Interf. Cyt. Research* 19:S85, 1999.
158. Platanius LC, Bruno E, Korkmaz M, Ahmad S, Alsayed Y, **Uddin S**, Van den Berg D, Druker B, Wickrema A and Hoffman R. Activation of the Crk-signaling pathway by interferon- $\alpha$  mediates its growth inhibitory effects on Normal hematopoietic progenitors. *Eur. J. Cytok. Net.* 9:354, 1998.
159. Platanius LC, **Uddin S**, Korkmaz M, Majchrzak B, Druker B and Fish EN. Interferon signaling via a CrkL- Stat5 DNA binding complex. *Blood* 92:576, 1998.
160. Grumbach I, Fish EN, **Uddin S**, Majchrzak B, Colamonici OR, Figulla HR, Heim A and Platanius LC. Activation of the Jak-Stat pathway in cells that exhibit selective sensitivity to IFN $\beta$  as compared to IFN $\alpha$ . *Blood* 92:545, 1998.
161. **Uddin S**, Fish EN, Alsayed Y, Colamonici OR, Khan MK and Platanius LC. Regulation of the PI 3'-kinase and downstream pathways by interferon  $\alpha$  (IFN $\alpha$ ) in hematopoietic cells. *Blood* 92:374, 1998.
162. Wickrema A, **Uddin S**, Chen F, Sharma A, Ahmad S, Sawyer ST and Platanius LC. Erythropoietin induces tyrosine phosphorylation of Grb2-associated binder-1 (Gab-1) and its interaction with the PI3'-kinase in primary erythroid progenitors. *Blood* 92:66a, 1998.
163. Wickrema A, Chen F, Namin F, Ahmad S, **Uddin S**, Chen YH, Yi T, Hoffman R and Platanius LC. Defective expression of the SHP-1 phosphatase in polycythemia vera. *Blood* 90, (Suppl. 1) 10:412a, 1997.
164. **Uddin S**, Fish EN, Sher D, Gardziola C, Colamonici OR, Pitha PM, White MF and Platanius LC. Differential function of insulin receptor substrate-1 (IRS-1) in IFN $\alpha$  and insulin/IGF-1 signaling in hematopoietic cells. *Blood* 88, (Suppl. 1) 10:197a, 1996.
165. Platanius LC, **Uddin S**, Domanski P and Colamonici OR. Differences in signaling between interferons  $\alpha$  and  $\beta$ : Interferon  $\beta$  selectively induces the interaction of the  $\alpha$  with the  $\beta$ L subunit of the Type I IFN receptor. *Blood* 88, (Suppl. 1) 10:546a, 1996.
166. **Uddin S**, Sher D, White MF and Platanius LC. Interferon-dependent interaction of Fyn with Jak kinases. *Blood* 88, (Suppl. 1) 10:196a, 1996.
167. Platanius LC, **Uddin S**, Yenush L, Sun XJ, Sweet ME and White MF. Type I interferons activate the insulin receptor substrate (IRS)-signaling system. *J. Interf. Cytok. Res.* 15:S12, 1995.
168. **Uddin S**, Yetter A and Platanius LC. Insulin-like growth factor-1 (IGF-1) induces tyrosine phosphorylation of the vav proto-oncogene product. *Proc. Am. Soc. Clin. Oncol.* 14:521, 1995.

169. **Uddin S**, Yetter A, Colamonici OR and Plataniias LC. Interferon  $\alpha$ -dependent tyrosine phosphorylation of the Tyk-2 tyrosine kinase in IFN $\alpha$ -sensitive and - resistant acute leukemia cell lines. *Blood* 84, (Suppl. 1), 10:626, 1994.
170. Plataniias LC, Katzav S, White MF and **Uddin S**. Insulin induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells. *Blood* 84, (Suppl. 1), 10:121, 1994.
171. Plataniias LC, Yenush L, Sun XJ, Sweet ME, White MF and **Uddin S**. Interferon  $\alpha$  engages an IRS-signaling protein to regulate the phosphatidylinositol 3'-kinase. *Blood* 84, (Suppl.1), 10:508, 1994.
172. Rahman A, **Uddin S**, Hadi SM, Parish JH and Ainley K. Strand scission in DNA induced by quercetin and Cu(II): Role of Cu(I) and oxygen free radicals. 3rd International Symposium on Flavonoids in Biology and Medicine, Singapore, November, 1989.
173. Rahman A and **Uddin S**. Interaction of methylglyoxal with DNA. 57th Annual Meeting of the Society of Biological Chemists, New Delhi, India, October 1988.
174. Hadi SM, **Uddin S** and Rahman A. Specificity of interaction of furfural with DNA. 14th International Congress of Biochemistry, Prague, Czechoslovakia, July 1988.
175. **Uddin S**, Rahman A and Hadi SM. Interaction of 5-methylfurfural with DNA. 56th Annual Meeting of the Society of Biological Chemists, Tirupati, India, November 1987.
176. Hadi SM, **Uddin S** and Rahman A. Interaction of methylfurfural with DNA. 9th International Biophysics Congress, Jerusalem, Israel, August 1987.
177. **Uddin S**, Rizvi RY, Rahman A and Hadi SM. Interaction of 5-methylfurfural and furfural with DNA. 55th Annual Meeting of the Society of Biological Chemists, Trivendrum, India, December 1986.
178. Rizvi RY, **Uddin S**, Rahman A and Hadi SM. Effect of alkylation with streptozotocin on the secondary structure of DNA. 4th Federation of Asian and Oceanian Biochemists, Singapore, November 1986.